Front. Cell Dev. Biol. Frontiers in Cell and Developmental Biology Front. Cell Dev. Biol. 2296-634X Frontiers Media S.A. 1261749 10.3389/fcell.2023.1261749 Cell and Developmental Biology Mini Review Tumour-associated macrophages: versatile players in the tumour microenvironment Ji et al. 10.3389/fcell.2023.1261749 Ji Zoey Zeyuan 1 † Chan Max Kam-Kwan 1 † Chan Alex Siu-Wing 2 Leung Kam-Tong 3 Jiang Xiaohua 4 To Ka-Fai 1 Wu Yi 5 Tang Patrick Ming-Kuen 1 * 1 Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China 2 Department of Applied Social Sciences, The Hong Kong Polytechnic University, Kowloon, Hong Kong SAR, China 3 Department of Paediatrics, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China 4 Key Laboratory for Regenerative Medicine of the Ministry of Education of China, School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China 5 MOE Key Laboratory of Environment and Genes Related to Diseases, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an, China

Edited by: Yu Zhao, Capital Medical University, China

Reviewed by: Yanruide Li, University of California, Los Angeles, United States

 *Correspondence: Patrick Ming-Kuen Tang, patrick.tang@cuhk.edu.hk

These authors have contributed equally to this work

 26 10 2023 2023 11 1261749 19 07 2023 12 10 2023 Copyright © 2023 Ji, Chan, Chan, Leung, Jiang, To, Wu and Tang. 2023 Ji, Chan, Chan, Leung, Jiang, To, Wu and Tang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Tumour-Associated Macrophages (TAMs) are one of the pivotal components of the tumour microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and anti-cancer activities are reported, including not only angiogenesis, extracellular matrix remodeling, immunosuppression, drug resistance but also phagocytosis and tumour regression. Interestingly, TAMs are highly dynamic and versatile in solid tumours. They show anti-cancer or pro-tumour activities, and interplay between the tumour microenvironment and cancer stem cells and under specific conditions. In addition to the classic M1/M2 phenotypes, a number of novel dedifferentiation phenomena of TAMs are discovered due to the advanced single-cell technology, e.g., macrophage-myofibroblast transition (MMT) and macrophage-neuron transition (MNT). More importantly, emerging information demonstrated the potential of TAMs on cancer immunotherapy, suggesting by the therapeutic efficiency of the checkpoint inhibitors and chimeric antigen receptor engineered cells based on macrophages. Here, we summarized the latest discoveries of TAMs from basic and translational research and discussed their clinical relevance and therapeutic potential for solid cancers.

 tumour-associated macrophages tumour microenvironment immunotherapy macrophage plasticity macrophage-myofibroblast transition macrophage-neuron transition 14106518 14111019 14111720 24102723 PDFS2122-4S06 10210726 PFP202210-004 4620528 178896941 4054722 NL/LT/PDFS 2022/0360/22lt WW/PDFS 2023/0640/23en Research Grants Council, University Grants Committee10.13039/501100002920 Hong Kong Government10.13039/501100017649 Chinese University of Hong Kong10.13039/501100004853 section-at-acceptance Cancer Cell Biology Introduction

Tumour microenvironment (TME) is crucial for cancer initiation, progression, and drug resistance. TME is formed by various fundamental constituents including stromal cells and immune cells (Cassetta et al., 2019; Li et al., 2023; Wang et al., 2023). Cancer development can be facilitated by tissue inflammation (Nost et al., 2021; Rajamaki et al., 2021). Despite the diverse inflammatory components in various cancer types (Cheng et al., 2021), increasing evidence demonstrated the importance of macrophages in the progression of solid cancers (Christofides et al., 2022). Macrophage is the key inflammatory effector cells, better understanding its roles may uncover effective therapeutic strategy for cancer (Coussens et al., 2013).

Interestingly, macrophages are versatile in tissues under inflammation including cancer (Maier et al., 2020; Vayrynen et al., 2021; Xue et al., 2021; Nalio Ramos et al., 2022). Their phenotypes and functions are broadly categorized into pro-inflammatory M1 and anti-inflammatory M2 (Cho et al., 2022; Zhou et al., 2022). M1 macrophages eliminate cancer cells by phagocytosis, antibody-dependent cytotoxicity, vascular damage, and tumour necrosis. M2 macrophages promote tumour growth and progression via enhancing cancer cell survival, angiogenesis and immune suppression (Zhao et al., 2020; Chen et al., 2021; Ren et al., 2022). Beyond M1/M2 polarization, new transition mechanisms for TAMs have been recently identified by single-cell bioinformatic studies including MMT (Tang et al., 2022a) and MNT (Tang et al., 2022b), their roles in cancer remain unclear.

Clinical studies highlight the crucial roles of macrophages in cancer therapy response and resistance, including chemotherapy, radiotherapy, and PDL1-based immunotherapy (Furuse et al., 2020; Liu et al., 2020). Moreover, clinical trials of macrophage-targeted therapies have been started such as the engineered mononuclear phagocytes (Brempelis et al., 2020) and chimeric antigen receptor macrophages (CAR-M) (Klichinsky et al., 2020; Wang et al., 2022), these therapeutic approaches stem from bench-top discoveries like recruitment and differentiation (Hannan et al., 2023), functional reprogramming (Willingham et al., 2012), and integration (Dang et al., 2021), highlighting the importance of basic research and preclinical study for the development of effective cancer treatment.

In this review, we systematically summarized the functional roles and underlying mechanisms of macrophages in TME for cancer formation and progression, their translational potential, and related studies on patients for overcoming the barriers of conventional cancer treatments as well as the latest immunotherapy resistance in the clinic. Finally, we also discussed the prospects and further directions of TAMs in the clinical development for cancer treatment.

 Physiological roles of macrophages

Macrophages release cytokines and chemokines for recruiting immune cells for wound healing and blood vessel formation (Hernandez et al., 2022), including vascular endothelial growth factor (VEGF) (Lu et al., 2020) and transforming growth factor-beta (TGF-β) (Chung et al., 2018). Macrophages maintain tissue integrity (Mosser et al., 2021), clearing apoptotic cells (Dooling et al., 2023), debris (Kim et al., 2020), and pathogens (Nau et al., 2002) via cell-mediated phagocytosis, where the targets are recognized by pattern recognition receptors (PRRs) dependent mechanisms (Li and Wu, 2021) i.e., Toll-like receptors (TLRs) (Irizarry-Caro et al., 2020) and NOD-like receptors (NLRs) (Fekete et al., 2018; Frising et al., 2022).

Furthermore, macrophages are involved in innate and adaptive immune responses by recognizing pathogen-associated molecular patterns (PAMPs) (Greene et al., 2022) and damage-associated molecular patterns (DAMPs) (Serbulea et al., 2018; Neu et al., 2022) through PRRs. Activated macrophages produce pro-inflammatory cytokines, i.e., tumour necrosis factor-alpha (TNF-α) (Lee et al., 2021; Lechner et al., 2022; Tanito et al., 2023) and interleukin-12 (IL-12) (Luo et al., 2022; Pfirschke et al., 2022), to promote inflammation and activate other immune cells. Macrophages also process and present antigens to T cells via major histocompatibility complex (MHC) molecules aiding adaptive immune response (Mascarau et al., 2023; van Elsas et al., 2023). Interestingly, tissue-specific macrophages display unique functions. For example, alveolar macrophages in lung, express high levels of surfactant protein A (SP-A) (Bain and MacDonald, 2022; Garcia-Fojeda et al., 2022; Yau et al., 2023) and surfactant protein D (SP-D) receptors (Guo et al., 2019; Hsieh et al., 2023) for clearing inhaled particles and pathogens. Liver-resident macrophages, Kupffer cells, express various scavenger receptors (Taban et al., 2022), complement receptors (Wen et al., 2021), and Fc receptors (Pfefferle et al., 2023), filtering blood-borne pathogens (Zhao et al., 2022a), toxins (Kermanizadeh et al., 2019), and debris (Liu and Sun, 2023).

Macrophages are classified into M1 and M2 phenotypes (Guilliams and Svedberg, 2021; De Vlaminck et al., 2022). M1 macrophages express high level of pro-inflammatory cytokines like Interleukin-1β (IL-1β), Interleukin-6 (IL-6), IL-12, Interleukin-23 (IL-23), and TNF-α (Hou et al., 2018; Akhtari et al., 2021; Beyranvand Nejad et al., 2021; Gunassekaran et al., 2021) polarized by Th1 cytokines including GM-CSF, TNF-α, and interferon-gamma (IFN-γ) (Wu et al., 2022a; Zhao et al., 2022b; Cho et al., 2022; Zhang et al., 2023), whereas, M2 macrophages actively produce anti-inflammatory cytokines Interleukin-10 (IL-10) and TGF-β (Nagata et al., 2019; Yang et al., 2023a) and polarized by Th2 cytokines like Interleukin-4 (IL-4) and Interleukin-13 (IL-13) (Celik et al., 2020; Lundahl et al., 2022). For metabolism, M1 macrophages rely on glycolysis (Yu et al., 2020; Mouton et al., 2023), while M2 macrophages depend on oxidative phosphorylation (Xu et al., 2021a; Zhou et al., 2022). During tissue repair, macrophages switch from an M1-like to an M2-like phenotype (Kim et al., 2019a; Alhamdi et al., 2019; Kohno et al., 2021). Interestingly, M1/M2 homeostasis is disrupted by inhibition of aspartate-aminotransferase (Wu et al., 2020a) and N-glycosylation (Wu et al., 2020a; Hu et al., 2023), altering immune responses and tissue damage. Moreover, various polarization and activation markers coexist in tissues, and factors like the macrophage-inducible C-type lectin (MINCLE) (Maier et al., 2020; Xue et al., 2021) or TLRs (Vidyarthi et al., 2018; Zhou et al., 2022) impact their balance. TAMs play multifaceted roles in cancer progression that are both beneficial and detrimental, highlighting the dual nature of their involvement (Figure 1).

TAMs play a complex dual role in the progression of cancer. M1 TAMs contribute to the anticancer response via multiple mechanisms. They can produce reactive oxygen species (ROS) and reactive nitrogen species (RNS) to cause oxidative damage and kill cancer cells. The secretion of pro-inflammatory cytokines and chemokines (e.g., TNF-α, IL1B, IL12A/B, CCL5, and CXCL10) can mobilize other anticancer immune cells, like T cells and NK cells, into the TME. Anti-angiogenesis is promoted by secretion of thrombospondin-1 and angiostatic chemokines like CXCL9, CXCL10, and CXCL11. TAMs also express MHC class I and II molecules for antigen presentation to further priming and activation of T cells. The interaction between CD80/CD86 on TAMs and CD28 on T cells provides a second signal for T cell activation. M2 TAMs promote immunosuppression, angiogenesis, and tumour growth/metastasis while contributing to drug resistance. Immunosuppression involves secretion of TGF-β and IL-10, expression of PD-L1, and CCL22-induced Treg activation. In angiogenesis, TAMs secrete factors like VEGF, FGFs, PDGF, HGF, MMPs, and IL-8/1. During tumour growth and metastasis, M2 TAMs enhance proliferation, migration, and invasion. Factors like EGF, PDGF, VEGF, CCL-10, and MMPs play key roles. TAM can also undergo transformation to MNT and MMT, resulting in the generation of cancer pain and cancer-associated fibroblast. In drug resistance, TAM-derived TGF-β, IL-6/8, and PDGF stimulate survival pathways and enhance DNA repair in cancer cells. It is noteworthy that macrophages can switch from M1 phenotype to M2 phenotype during tissue repair.

 Anticancer effects of TAMs Reactive species production

M1 TAMs produce reactive oxygen species (ROS), mediated by NADPH oxidase (Fang et al., 2022; Tlili et al., 2023), causing cancer cell death. Activation by IFN-γ and TNF-α prompts TAMs to generate reactive nitrogen species (RNS) via nitric oxide synthase (iNOS) (Zhang et al., 2021a; Wei et al., 2022). Collectively, these ROS and RNS induce oxidative damage on cancer cells, leading to direct cancer cell-killing effect (Liang et al., 2019; Huang et al., 2022; Qi et al., 2022; Kidwell et al., 2023).

 Pro-inflammatory cytokine and chemokine

TAMs secrete pro-inflammatory cytokines for mobilizing anticancer cells (e.g., T cells and natural killer cells) into TME, including TNF-α (Jiang et al., 2019; Kaplanov et al., 2019; Tu et al., 2021a), IL1B (interleukin-1 beta) (Revu et al., 2018), IL12A and IL12B (subunits of IL-12) (Yen et al., 2022). TAMs also produce chemokines, e.g., C-C Motif Chemokine Ligand 5 (CCL5) and C-X-C motif chemokine ligand 10 (CXCL10) to recruit and activate other immune cells to TME, driven by pro-inflammatory transcription factor NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells) (Taki et al., 2018). Furthermore, M1 macrophages produce IL-12, prompting CD4+ T cells towards Th1 phenotype (Zhao et al., 2022b), these Th1 cells will produce IFN-γ to activate cytotoxic CD8+ T cells in TME (Greaney et al., 2020; Liu et al., 2022). M1 macrophages also stimulate NK cell activation by IL-12, IL-15 and IL-18 (Mattiola et al., 2015).

 Anti-angiogenesis

M1 macrophages secrete angiostatic factor thrombospondin-1(TSP1) (Yang et al., 2019; Kumar et al., 2020) for inhibiting angiogenesis by interacting with an endothelial cell receptor CD36 in various cancers, including hepatocellular carcinoma (Aburima et al., 2021). Moreover, M1 macrophages produce additional angiostatic chemokines to block vessel formation via CXCR3 (C-X-C Motif Chemokine Receptor 3) dependent mechanism, including CXCL9, 10, 11 (C-X-C Motif Chemokine Ligand 9, 10, 11) (Romagnani et al., 2004; Sahraei et al., 2019).

 Antigen presentation

M1 macrophages express MHC class I and II molecules (Haloul et al., 2019; Ahmed and Ismail, 2020) to present cancer antigens, involving several genes, including MHC class I (Yao et al., 2020; Desterke et al., 2021; Piatakova et al., 2021) and II (He et al., 2021; Tang et al., 2022c; Scavuzzi et al., 2022). The interaction of MHC molecules with T cell receptors amplifies anti-tumour host immune response (Guerriero, 2019; Kawasaki et al., 2022). Interaction between CD80 and CD86 on the M1 macrophage and CD28 on the T cell also provides crucial second signal for T cell activation (Trzupek et al., 2020).

 Pro-tumour effects of TAM Immunosuppression

TAMs contribute to immunosuppression in TME, including lung adenocarcinoma (LUAD) and bladder cancer (BLCA). They inhibit the anticancer activities of NK cells primarily through producing TGF-β (Nunez et al., 2018) and IL-10 (Xu et al., 2022). TGF-β hampers NK cell cytotoxicity by downregulating NKG2D receptor expression (Lazarova and Steinle, 2019). IL-10 inhibits the production of the anticancer cytokine IFN-γ in NK cells (Wang et al., 2021a). TAMs in these diverse cancer types express programmed death-ligand 1 (PD-L1) (Sumitomo et al., 2019; Shinchi et al., 2022; Xia et al., 2022; Elomaa et al., 2023), which interacts with the PD-1 receptor on T cells (Pereira et al., 2023; Puig-Saus et al., 2023) and NK cells (Zhou et al., 2023a; van der Sluis et al., 2023), leading to their exhaustion and promoting tumour immune evasion. TAM-derived CCL22 (C-C Motif Chemokine Ligand 22) contributes to the recruitment and activation of regulatory T cells (Tregs) (Rapp et al., 2019; Chen et al., 2022a), inducing immunosuppression in TME (Kraaij et al., 2010; Erlandsson et al., 2019). TAMs also enhance immunosuppressive function of Tregs, promote the transition of conventional CD4+ T cells into Tregs (Morhardt et al., 2019; Saraiva et al., 2020; Maldonado et al., 2022), and activate myeloid-derived suppressor cells (MDSCs) via IL-10 (Yu et al., 2018; Yogev et al., 2022) and TGF-β (Becker et al., 2018; Astarita et al., 2023). Furthermore, TAMs express immune checkpoint molecule cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (Guan et al., 2021), interacting with CD80/CD86 of Tregs to amplify their immunosuppressive effects (Zappasodi et al., 2021; Kennedy et al., 2022).

 Angiogenesis

TAMs play pivotal role in augmenting angiogenesis within the TME, integral to cancer progression (Cheng et al., 2021). Essential for tumor growth and metastasis (Liu et al., 2023a; Natale and Bocci, 2023), angiogenesis provides TME with necessary nutrients and oxygen, aiding in the growth of cancer cells (Schaaf et al., 2018; Lugano et al., 2020; Schito and Rey, 2020). TAMs secret factors for promoting angiogenesis, including VEGF (Schaaf et al., 2018), fibroblast growth factors (FGF1 and FGF2) (Schaaf et al., 2018; Im et al., 2020), platelet-derived growth factor (PDGF) (Ntokou et al., 2021), hepatocyte growth factor (HGF) (Choi et al., 2019; Dong et al., 2019), matrix metalloproteinases (MMP-9, MMP-2) (Diwanji and Bergmann, 2020; Tian et al., 2022), and cytokines like IL-8 and IL-1 (Liu et al., 2023b; Yang et al., 2023b). VEGF is crucial for tumoural angiogenesis (Lai et al., 2019; Hwang et al., 2020). Moreover, TAMs are concentrated in the hypoxic zones of tumours (Bai et al., 2022), where they upregulate the expression of numerous angiogenic genes including Hypoxia-inducible factors (HIF)-1 and −2 (Jeong et al., 2019; Cowman et al., 2020) for enhancing the production of angiogenic factors like VEGF in TME (Roda et al., 2012).

 Cancer growth and metastasis

M2 TAMs promote primary tumour development and metastasis (Yao et al., 2018; Li et al., 2019a; Tu et al., 2021b). They increase tumour proliferation in breast cancer (Chen et al., 2022b; Zhou et al., 2023b), endometrial cancer (Xiao et al., 2020; Gu et al., 2021), and renal cell carcinoma (Xie et al., 2021; Ishii et al., 2022). Furthermore, M2 TAMs secrete Epidermal Growth Factor (EGF) (Zeng et al., 2019; Wu et al., 2020b), which binds to EGFR on cancer cells, for activating their growth signaling including MAPK/ERK (Liang et al., 2022) and PI3K/Akt pathways (Zhang et al., 2021b), promoting cell motility and invasion (Haque et al., 2019; Zeng et al., 2019; Onal et al., 2021). Growth Factor PDGF (Turrell et al., 2023) secreted from TAMs also contributes to tumour cell proliferation. Tumour metastasis is defining characteristic of advanced cancer stage, TAM-derived EGF accelerates metastasis by activating the EGFR-ERK signaling and inhibiting the expression of lncRNA LIMT (Zeng et al., 2019) in the epithelial ovarian cancer.

At the pre-metastasis stage, TAMs secrete VEGF, CCL-10 and MMPs, which remodel distant tissues to create pre-metastatic niche (Kim et al., 2019b; Winkler et al., 2020). TAMs release inflammatory factors TNF-α, IL-6, and IL-11 (Kaplanov et al., 2019; Yu et al., 2019; Beyranvand Nejad et al., 2021) to enhance cancer cell survival and proliferation by activating NF-κB and STAT3 pathways (Dorrington and Fraser, 2019; Balic et al., 2020). TGF-β from TAMs activates TGF receptors on cancer cells, initiating SMAD signaling for their growth (Chung et al., 2023; Lv et al., 2023). Importantly, TAM-derived TGF-β induces epithelial-to-mesenchymal transition (EMT) of cancer cells (Cai et al., 2019; Tiwari et al., 2021), allowing them to migrate into surrounding tissue and vasculature (Dongre and Weinberg, 2019; Wang et al., 2021b). Additionally, TAMs-secreted MMPs, such as MMP2 and MMP9 (Wang and Khalil, 2018; Liu et al., 2019; Muniz-Bongers et al., 2021), degrade the ECM in TME (Marigo et al., 2020), enabling metastasis into the bloodstream or lymphatic system (Winkler et al., 2020). TAMs produce chemokines like CCL18 and CCL22 (She et al., 2018; Kimura et al., 2019; Zhou et al., 2019; Chen et al., 2022a) to promote tumour cell migration. TAMs also release proteases like cathepsins (CTSB, CTSD) (Loeuillard et al., 2020; Shi et al., 2022) to stimulate tumour cells to produce tissue inhibitors of metalloproteinases, enhancing ECM degradation and metastasis (Bissinger et al., 2021).

TAMs transformation also contributes to cancer progression. Besides M1/M2 polarization, single-cell RNA-sequencing revealed new TAM phenomena. Macrophage to MNT, a process where TAMs transform into neuron-like cells contributing to the formation of cancer pain (Tang et al., 2022b). MMT, where TAMs trans-differentiate into myofibroblasts for increasing abundance of pro-tumour cancer-associated fibroblasts (CAFs) in TME, enhancing the progression of non-small-cell lung carcinoma (NSCLC) (Tang et al., 2022a).

 Drug resistance

TAMs are associated with resistance of cancer therapy (Mantovani et al., 2022). TAM-derived TGF-β upregulates the expression of multidrug resistance protein 1 (MDR1) in cancer cells (Badmann et al., 2020), leading to drug resistance. TAMs secrete IL-6 and IL-8 (Ahmed et al., 2021; Radharani et al., 2022), associated with resistance to therapies including EGFR tyrosine kinase inhibitors. TAMs-secreted PDGF enhances DNA repair in cancer cells against radiation therapy (Sakama et al., 2021).

 Interplay between TME and cancer stem cells

The dynamic relationship between the TME and cancer stem cells (CSCs) is central to understanding the roles of TAMs. CSCs, distinguished by their pronounced expression of stemness markers like SOX2, NANOG, and OCT4 (Zhou et al., 2021), actively drive self-renewal, differentiation, and are influenced by signals from TME (Yang et al., 2020). Key pathways such as TGF-β, Wnt, and Hedgehog (Li et al., 2019b; Zhu et al., 2019; Wu et al., 2022b) mold the genetic landscape of CSCs. The crosstalk between CSCs and TME involves factors including IL-6 (Orange et al., 2023), IL-8 (Sun et al., 2018), IL-1β (Eyre et al., 2019), MMPs (Jin and Jin, 2020), VEGF (Lopez de Andres et al., 2020), and TGF-β1 (Yuan et al., 2022), which are encapsulated within extracellular vehicles (EVs) (Su et al., 2021; Cao et al., 2022). Given the immunomodulatory role of CSCs, further studies are essential to understand the clinical implications.

Importantly, interaction between TAMs and CSCs fosters an immunosuppressive TME (Wu et al., 2023). CSCs promote macrophage recruitment and polarization by ILs, ECM, TGF-β, and periostin (Ning et al., 2018; Kesh et al., 2020; Taniguchi et al., 2020; Li et al., 2022a; Lin et al., 2022). Moreover, TAMs increase CD47 expression in pancreatic, liver and lung cancer stem cells (Cioffi et al., 2015; Liu et al., 2017; Ruiz-Blazquez et al., 2021). When linked to SIRPα on macrophages, CD47 expression protects CSCs against immune cell-mediated phagocytosis (Li et al., 2018). TAM-secreted factors also upregulate immunological checkpoints like PD-L1 (Muraoka et al., 2019; Pu and Ji, 2022). The intricate interplay between CSCs and TAMs creates immunosuppressive TME, enhancing the survival of CSC and hindering tumour eradication post-immunotherapy.

 Macrophage-targeted antitumour therapy

TAMs are essential for cancer immunotherapy (Lin et al., 2019). Macrophage-targeted treatments often deplete macrophages, modify their phenotypes, or enhance antigen presentation activity of TAM (Cassetta and Pollard, 2018). Combined with chemotherapy, radiation, or immunotherapy, these techniques may increase host antitumor immunity. They have been studied in animal models and clinical studies with immunological checkpoints and other immunotherapies (Table 1).

Selected clinical trials of drugs targeting TAMs.

Compound Clinical phase Tumour type Status NCT identifier Year
CSF1R inhibitors
PLX3397 Phase1 Drug Interaction Potential Completed NCT03291288 2017
Phase3 Tenosynovial Giant Cell Tumour Active_Not_Recruiting NCT04488822 2020
Phase4 Tenosynovial Giant Cell Tumour Active_Not_Recruiting NCT04526704 2020
Phase2 Tenosynovial Giant Cell Tumour Recruiting NCT04703322 2021
HMPL-012 Phase2 Advanced Solid Tumours Completed NCT04169672 2019
Phase2 Thyroid Cancer Unknown NCT04524884 2020
Phase2 Neuroendocrine Tumours Active_Not_Recruiting NCT04579679 2020
Phase2 Advanced Colorectal Cancer Not_Yet_Recruiting NCT04734249 2021
Phase2 Advanced Colorectal Cancer Recruiting NCT04764006 2021
Phase2 Advanced Non-Small Cell Lung Cancer Recruiting NCT04922658 2021
Phase1 and 2 Advanced Colorectal Cancer Recruiting NCT04929652 2021
Phase1 Small Cell Lung Carcinoma Recruiting NCT04996771 2021
Phase2 Carcinoma, Non-Small-Cell Lung Recruiting NCT05003037 2021
Phase2 Refractory Metastatic Digestive System Carcinoma and Peritoneal Cancer Recruiting NCT05030246 2021
Na Biliary Tract Cancer Recruiting NCT05056116 2021
Phase1 Neuroendocrine Tumours and Non-hematologic Malignancy Recruiting NCT05077384 2021
Phase1 and 2 Solid Tumour Active_Not_Recruiting NCT05093322 2021
Phase2 Neuroendocrine Neoplasm Recruiting NCT05165407 2021
Phase2 Hepatocellular Carcinoma Recruiting NCT05171439 2021
Phase2 Breast Cancer and Breast Cancer Female Recruiting NCT05186545 2022
Phase1 and 2 Pancreatic Cancer Recruiting NCT05218889 2022
Phase2 Gastric Adenocarcinoma Not_Yet_Recruiting NCT05235906 2022
Phase2 Pancreatic Neoplasms Not_Yet_Recruiting NCT05481463 2022
Phase2 Pancreatic Neoplasms Not_Yet_Recruiting NCT05481476 2022
Phase2 Advanced Solid Tumours Not_Yet_Recruiting NCT05527821 2022
Phase2 Small Cell Lung Cancer Not_Yet_Recruiting NCT05595889 2022
Phase2 Pancreatic Carcinoma Recruiting NCT05627427 2022
Phase2 Extensive-stage Small-cell Lung Cancer Not_Yet_Recruiting NCT05668767 2022
Phase1 and 2 Metastatic Triple-negative Breast Cancer Not_Yet_Recruiting NCT05746728 2023
Phase1 and 2 Unresectable Locally Advanced Not_Yet_Recruiting NCT05832892 2023
Phase1 and 2 Small Cell Lung Cancer Not_Yet_Recruiting NCT05882630 2023
Phase2 Pancreatic Cancer Recruiting NCT05908747 2023
DCC-3014 Phase1 Advanced Sarcoma cancer Active_Not_Recruiting NCT04242238 2020
Phase3 Giant Cell Tumour Active_Not_Recruiting NCT05059262 2021
Phase1 and 2 Advanced Malignant Neoplasm Recruiting NCT03069469 2017
CS2164 Phase1 Small Cell Lung Cancer Recruiting NCT03216343 2017
Phase1 and 2 Ovarian Cancer Completed NCT03166891 2017
Phase2 Ovarian Cancer Completed NCT03901118 2019
Phase3 Small Cell Lung Cancer Recruiting NCT04830813 2021
Phase3 Ovarian Cancer and Relapsed or Refractory and Chiauranib and Paclitaxel Recruiting NCT04921527 2021
Phase1 and 2 Small-cell Lung Cancer and Advanced Solid Malignant Tumour Recruiting NCT05271292 2022
Q702 Phase1 Solid Tumour and Advanced Cancer and Metastatic Cancer Recruiting NCT04648254 2020
Phase1 and 2 Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer and Cervical Cancer Recruiting NCT05438420 2022
TPX-0022 Phase1 and 2 Advanced Solid Tumour Active_Not_Recruiting NCT03993873 2019
X-82 Phase1 Solid Tumour Terminated NCT03511222 2018
Phase1 and 2 Thymic Carcinoma, Non-small Cell Lung Cancer and Small-Cell Lung Cancer Active_Not_Recruiting NCT03583086 2018
Phase1 Advanced Malignant Solid Tumours Active_Not_Recruiting NCT03792958 2019
Phase2 Extensive-stage Small Cell Lung Cancer Active_Not_Recruiting NCT04373369 2020
Chemokine inhibitors
BMS-813160 Phase1 and 2 Colorectal Cancer and Pancreatic Cancer Active_Not_Recruiting NCT03184870 2017
Phase1 and 2 Pancreatic Ductal Adenocarcinoma Active_Not_Recruiting NCT03496662 2018
Phase1 and 2 Locally Advanced Pancreatic Ductal Adenocarcinoma Recruiting NCT03767582 2018
Phase2 Non-small Cell Lung Cancer and Hepatocellular Carcinoma Recruiting NCT04123379 2019
Maraviroc Phase1 Metastatic Colorectal Cancer and MSS Completed NCT03274804 2017
Phase1 Colorectal Cancer Metastatic and Pancreatic Cancer Metastatic Unknown NCT04721301 2021
Phase1 and 2 HIV and Hematologic Malignancies Recruiting NCT05470491 2022
Anti-CD47/SIRPα antibodies
Hu5F9-G4 Phase1 Hematological Malignancies Active_Not_Recruiting NCT03248479 2017
Phase1 Ovarian Cancer Completed NCT03558139 2018
Phase1 Acute Myeloid Leukemia Terminated NCT03922477 2019
Phase1 and 2 Mycosis Fungoides and Recruiting NCT04541017 2020
Phase1 Follicular Lymphoma Recruiting NCT04599634 2020
Phase1 High Risk Neuroblastoma, Recurrent Neuroblastoma and Resectable Osteosarcoma Suspended NCT04751383 2021
Phase2 Myeloid Malignancies Active_Not_Recruiting NCT04778410 2021
Phase2 Solid Tumour Recruiting NCT04827576 2021
Phase2 Triple-Negative Breast Cancer Recruiting NCT04958785 2021
Phase1 Brain Cancer Recruiting NCT05169944 2021
Phase2 Metastatic Colorectal Cancer Recruiting NCT05330429 2022
Phase1 Advanced Malignant Solid Neoplasm Not_Yet_Recruiting NCT05807126 2023
BI 754091 Phase1 Neoplasms and Carcinoma, Non-Small-Cell Lung Completed NCT03156114 2017
Phase1 Neoplasms and Neoplasm Metastasis and Carcinoma, Non-Small-Cell Lung Terminated NCT03166631 2017
Early_Phase1 Neoplasms Active_Not_Recruiting NCT03433898 2018
Phase1 Non-squamous, Non-Small-Cell Lung Cancer and Neoplasms Active_Not_Recruiting NCT03468426 2018
Phase2 Neoplasm Metastasis Active_Not_Recruiting NCT03697304 2018
Phase1 Carcinoma, Non-Small-Cell Lung and Head and Neck Neoplasms Terminated NCT03780725 2018
Phase1 Neoplasms Recruiting NCT03964233 2019
Phase1 Neoplasms Completed NCT03972150 2019
Phase1 Solid Tumour, Adult Recruiting NCT03990233 2019
Phase1 and 2 Colorectal Cancer Recruiting NCT04046445 2019
Phase1 Neoplasm Completed NCT04138823 2019
Phase1 Neoplasms Active_Not_Recruiting NCT04147234 2019
Phase2 Anal Canal Squamous Cell Carcinoma Withdrawn NCT04499352 2020
Phase1 Solid Tumours Completed NCT04653142 2020
Phase2 Squamous Cell Carcinoma Recruiting NCT04719988 2021
Phase1 Colorectal Neoplasms, Carcinoma and Non-Small-Cell Lung Recruiting NCT04752215 2021
Phase1 Neoplasms Recruiting NCT04958239 2021
Phase1 Head and Neck Squamous Cell Carcinoma Recruiting NCT05249426 2022
Phase1 Solid Tumours Recruiting NCT05471856 2022
ALX148 Phase1 Metastatic Cancer and Solid Tumour and Advanced Cancer and NonHodgkin Lymphoma Active NCT03013218 2017
Phase2 and 3 Gastric Cancer Recruiting NCT05002127 2021
Phase1 and 2 HER2-expressing Cancers Recruiting NCT05027139 2021
Phase2 Microsatellite Stable Metastatic Colorectal Cancer Recruiting NCT05167409 2021
Phase2 Ovarian Cancer Recruiting NCT05467670 2022
Phase2 Oropharynx Cancer Not_Yet_Recruiting NCT05787639 2023
Phase1 HER2-positive Breast Cancer and Metastatic Cancer Recruiting NCT05868226 2023
AO-176 Phase1 and 2 Solid Tumour Active_Not_Recruiting NCT03834948 2019
IBI188 Phase1 Advanced Malignancies Completed NCT03763149 2018
SRF231 Phase1 Advanced Solid Cancers and Hematologic Cancers Completed NCT03512340 2018
Agonist anti-CD40 antibodies
SEA-CD40 Phase2 Melanoma and Carcinoma, Non-Small- Cell Lung Active_Not_Recruiting NCT04993677 2021
APX005M Phase1 and 2 Solid Cancers Completed NCT03123783 2017
Phase2 Esophageal Cancer, Gastric Cancer and Hepatocellular Cancer Active_Not_Recruiting NCT03165994 2017
Phase1 Glioblastoma Multiforme, Nos and Ependymoma, NOS and Medulloblastoma Active_Not_Recruiting NCT03389802 2018
Phase1 Advanced Melanoma, Non-small Cell Lung Cancer and Renal Cell Carcinoma Active_Not_Recruiting NCT03502330 2018
Phase1 Metastatic Melanoma Terminated NCT03597282 2018
Phase2 Soft Tissue Sarcoma Recruiting NCT03719430 2018
Phase2 Locally Advanced Rectal Adenocarcinoma Active_Not_Recruiting NCT04130854 2019
Phase2 Ovarian Cancer Not_Yet_Recruiting NCT05201001 2022
Phase1 and 2 Pancreatic Cancer Recruiting NCT05419479 2022
CDX-1140 Phase1 Solid Tumours Completed NCT03329950 2017
Phase1 and 2 Non-Small Cell Lung Cancer Recruiting NCT04491084 2020
Phase1 Malignant Epithelial Neoplasms Recruiting NCT04520711 2020
Phase2 Pancreatic Cancer Recruiting NCT04536077 2020
Phase1 Breast Cancer and Melanoma Recruiting NCT04616248 2020
Phase1 Metastatic Triple Negative Breast Cancer Recruiting NCT05029999 2021
Phase2 Solid Tumours Not_Yet_Recruiting NCT05231122 2022
Phase1 Malignant Epithelial Neoplasms Enrolling_By_Invitation NCT05349890 2022
NG-350A Phase1 Metastatic Cancer and Epithelial Tumour Completed NCT03852511 2019
Phase1 Epithelial Tumour and Metastatic Cancer Recruiting NCT05165433 2021
TLR agonists
Imiquimod Phase1 Carcinoma, Non-Small-Cell Lung Cancer Unknown NCT03057340 2017
Early_Phase1 Cervical Intraepithelial Neoplasia Active_Not_Recruiting NCT03196180 2017
NA Cervical Intraepithelial Neoplasia 3 Unknown NCT03206138 2017
Phase2 High Grade Intraepithelial Neoplasiaand Cervix Cancer Completed NCT03233412 2017
Phase2 Basal Cell Carcinoma, Basal Cell Carcinoma of Skin and Invasive Carcinoma Recruiting NCT03534947 2018
Phase1 and 2 Primary/Relapsed Acute Lymphoblastic Leukemia (ALL) of Childhood, Adolescents and Young Adults Unknown NCT03559413 2018
Phase1 Solid Tumours Recruiting NCT03872947 2019
Phase1 Malignant Glioma Recruiting NCT03893903 2019
Phase1 Metastatic Breast Cancer Terminated NCT03982004 2019
Phase1 Melanoma Unknown NCT04072900 2019
Early_Phase1 Basal Cell Carcinoma Completed NCT04279535 2020
Phase1 Glioblastoma Active_Not_Recruiting NCT04642937 2020
Early_Phase1 Oral Cancer Recruiting NCT04883645 2021
Phase1 Bladder Cancer and Bladder Recruiting NCT05055050 2021
Phase3 Basal Cell Carcinoma Not_Yet_Recruiting NCT05212246 2022
Phase1 Bladder Cance Recruiting NCT05375903 2022
Resiquimod Phase1 Tumours Completed NCT00821652 2009
Phase1 and 2 Advanced Malignancies Completed NCT00948961 2009
Phase2 Melanoma Completed NCT00960752 2009
Phase2 Bladder Cancer Terminated NCT01094496 2010
Phase2 Glioma and Glioblastoma Active_Not_Recruiting NCT01204684 2010
Early_Phase1 Recurrent Melanoma Completed NCT01748747 2012
Phase1 and 2 Melanoma Unknown NCT02126579 2014
Phase4 Postoperative Pain Completed NCT03570541 2018
Phase1 and 2 Advanced Solid Tumour Recruiting NCT04799054 2021
Phase1 and 2 Non-muscle-invasive Bladder Cancer Recruiting NCT05710848 2023
CpG ODN Phase2 Lymphoma, Mantle-Cell Completed NCT00490529 2007
Early_Phase1 Breast Cancer Completed NCT00640861 2008
Phase2 Breast Cancer Terminated NCT00824733 2009
Phase1 Melanoma Completed NCT01149343 2010
Phase2 Malignant Melanoma Recruiting NCT04126876 2019
Phase1 Pancreatic Cancer and Metastatic Pancreatic Cancer Recruiting NCT04612530 2020
Phase1 Lung Cancer and Hepatocellular Carcinoma and Solid Tumour Recruiting NCT04952272 2021
Poly(I:C) Phase1 Prostate Cancer Completed NCT03412786 2018
Phase1 Leiomyosarcoma Active_Not_Recruiting NCT04420975 2020
Early_Phase1 Advanced Hepatocellular Carcinoma Terminated NCT04777708 2021
CMP-001 Phase1 and 2 Advanced Cancer Terminated NCT02554812 2015
Phase1 Non-Small Cell Lung Cancer Completed NCT03438318 2018
Phase1 Colorectal Neoplasms Malignant and Liver Metastases Completed NCT03507699 2018
Phase2 Melanoma and Lymph Node Cancer Active_Not_Recruiting NCT03618641 2018
Phase1 and 2 Lymphoma Recruiting NCT03983668 2019
Phase1 and 2 Locally Advanced Malignant Solid Neoplasm Terminated NCT04387071 2020
Phase2 Melanoma Recruiting NCT04401995 2020
Phase2 Squamous Cell Carcinoma of Head and Neck Active_Not_Recruiting NCT04633278 2020
Phase2 Triple Negative Breast Cancer Recruiting NCT04807192 2021
Phase2 Merkel Cell Carcinoma, Triple Negative Breast Cancer and Non-Small Cell Lung Cancer Recruiting NCT04916002 2021
Phase3 Solid Tumours Recruiting NCT05059522 2021
Phase2 Multiple Primary Cancers Not_Yet_Recruiting NCT05164510 2021
Phase2 Metastatic Prostate Adenocarcinoma Not_Yet_Recruiting NCT05445609 2022
TREM2 inhibitor
PY314 Phase1 Advanced Solid Tumour Recruiting NCT04691375 2020
Clever 1 inhibitor
FP-1305 Phase1 and 2 Cancer Recruiting NCT03733990 2018
Phase1 Non-small Cell Lung Cancer Not_Yet_Recruiting NCT05171062 2021
Phase1 and 2 Acute Myeloid Leukemia Recruiting NCT05428969 2022
Complement inhibitor
IPH5401 Phase1 Advanced Solid Tumours Terminated NCT03665129 2018
Macrophage cell therapy
CT-0508 Phase1 Solid Tumours NCT04660929 2020
TEMFERON Phase1 and 2 Glioblastoma Multiforme Recruiting NCT03866109 2019
Phase1 and 2 Multiple Myeloma Terminated NCT03875495 2019
Depletion of macrophages

TAM recruitment by CCL2 and CCR2 is critical to tumour invasion and metastasis (Xu et al., 2021b). CCL2-CCR2 signaling controls the supply of circulating inflammatory monocytes (Argyle and Kitamura, 2018) and inhibiting CCR2 keeps monocytes in bone marrow, reducing TAMs at cancer sites (Flores-Toro et al., 2020). Blocking CCL2-CCR2 axis also hinders TAM recruitment, decreasing tumour incidence and enhancing CD8+ T cells anti-tumour activity (Teng et al., 2017; Tu et al., 2020). Another target is CSF-1, which promotes monocyte and macrophage differentiation, proliferation, and function (Stanley and Chitu, 2014). Mouse models with CSF-1R inhibition had smaller tumors and better survival (Tan et al., 2021). Small molecule inhibitors of CSF1-R have also been shown to deplete some TAMs, enhancing tumour sensitivity to chemotherapy (O'Brien et al., 2021).

 Alteration of macrophage phenotypes

TAMs change into a tumour-suppressing phenotype (Liu et al., 2021) which is a promising clinical strategy for cancer treatment. Inducing M1 macrophage phenotype through the use of selective class IIa HDAC inhibitors (Li et al., 2021a) enhances T cell responses to chemotherapy and immune checkpoint blockades (McCaw et al., 2019). The CD47/SIRP-α pathway is crucial for tumour immune escape, and blocking it enhances macrophages immune killing against tumours (Wang et al., 2020; Jia et al., 2021). Cancer immunotherapy research has also focused on anti-PD-1/PD-L1 treatment (Tomlins et al., 2023). TAMs, particularly M2 TAMs, express PD-L1 on their surface and contribute to immunosuppression by promoting T-cell apoptosis (Li et al., 2022b; Shinchi et al., 2022). In vitro-transcribed mRNA could stimulate effector molecule synthesis or cell reprogramming. mRNA in an injectable nanocarrier genetically reprogrammed TAMs into antitumour effectors. Nanoparticles formulated with mRNAs encoding the transcription factor interferon regulatory factor 5 (IRF5) and its activating kinase, inhibitor of NF-B kinase subunit-β (IKKβ), reversed the immunosuppressive TME and reprogrammed TAMs, regressing tumours in mouse cancer models (Zhang et al., 2019; Petty et al., 2021). The LILRB family, specifically LILRB2, is integral to the immune evasion strategies of cancer cells (Chen et al., 2018). LILRB2, an MHC-binding protein rich in TAMs, interacts with MHC class I molecules, which cancer cells often downregulate to dodge T cell recognition (Liu et al., 2023c). Blocking LILRB2 enhances macrophage pro-inflammatory and phagocytic activity. Its effect on macrophage activation and phagocytosis is unknown (Chen et al., 2018). MK-4830, an antibody against LILRB2, showed promising results in early trials with advanced-stage tumours (Siu et al., 2022). Responses correlated with the expression of pro-inflammatory cytokines and enhanced cytotoxic T cell-mediated anti-tumour immune response (Sharma et al., 2021). These approaches have been tested with other clinical used immunotherapies like immune checkpoints for their clinical potential with animal models and clinical trials.

 Antigen presentation enhancement

Scavenger receptors on TAMs are becoming therapeutic targets for their role in promoting TME pro-inflammatory shifts. Scavenger receptor CD163 is associated to tumour progression in several malignancies but the mechanism is unclear (Xie et al., 2022). However, CD163+ macrophage depletion causes tumor regression and re-establish anti-PD1 treatment response (Etzerodt et al., 2019). Macrophage mannose receptor 1 (MRC1), also known as CD206, affects tumour immunity (Rahabi et al., 2020). Its activation induces immunosuppressive macrophages. Intriguingly, MRC1-binding peptide RP-182 converts TAMs into anti-tumour M1-like effector cells (Jaynes et al., 2020). The collagenous macrophage receptor (MARCO) is abundantly present on TAMs. Targeting MARCO potentially reprogrammes TAMs from tumour-supportive to pro-inflammatory effectors (Sa et al., 2020; La Fleur et al., 2021). Another scavenger receptor Clever 1 also suppresses macrophages and T helper 1 lymphocytes (Virtakoivu et al., 2021). Blocking it switches TAMs from immunosuppressive to pro-inflammatory (Viitala et al., 2019). Triggering receptor expressed on myeloid cells 2 (TREM2), upregulated on TAMs in human and mouse tumours, is a potential target (Katzenelenbogen et al., 2020; Molgora et al., 2020). Blocking TREM2+ macrophages limit tumour growth and augment anti-PD1 therapy (Binnewies et al., 2021). PSGL1, highly expressed in TAMs, represents a valuable target for TAMs re-education (Johnston et al., 2019). Using anti-PSGL1 monoclonal antibody potentially triggers a pro-inflammatory response in tumour tissues, exhibiting notable antitumour activity (DeRogatis et al., 2022; Lin et al., 2023).

 Innovative strategies for TAM modulation

Recent strategies explore TAM modulation. One approach involves the engineering of T cells with chimeric antigen receptors (CAR) (Maalej et al., 2023) specifically tailored to recognize and eliminate TAMs. Research shows CAR T cells targeting macrophages are effective against various solid organ tumours, including ovarian and pancreatic cancer (Sanchez-Paulete et al., 2022). Eliminating M2-like FRβ+ TAMs in the murine models of ovarian cancer, colon cancer and melanoma TME through FR-specific CAR-T cells delay tumour progression and prolong life (Rodriguez-Garcia et al., 2021). These CAR-engineered T cells show potential in redirecting immune responses against the tumour. Another method focuses on harnessing invariant natural killer T (iNKT) cells (Li et al., 2021b). These cells possess innate and adaptive immune properties, CAR-iNKT cells use iNKT TCR/CD1d and CAR recognition to deplete TAMs and tumours (Simonetta et al., 2021). Recent studies harness iNKT cells to modulate TAMs, boosting antitumour responses. Other innate T cells, including MAIT, and γδT cells, have potential clinical applications as they target and eliminate TAMs (Li et al., 2022c). In synthesis, these innovative strategies signify a shift in tumour immunotherapy (Table 2).

Innovative strategies targeting TAMs in tumour microenvironment.

Cell type Tumour type Function
FRβ.CAR-T Ovarian, Pancreatic, Colon, Melanoma Recognize and eliminate TAMs, delay tumour progression and prolong life
F4.CAR-T Orthotopic Lung Tumours Deplete TAMs, inhibit tumour growth, enhance MHC upregulation via IFNγ, and boost CD8 T cell expansion and tumour cell immune editing
iNKT Melanoma, Multiple myeloma, Ovarian Use iNKT TCR/CD1d and CAR recognition to deplete TAMs
γδT Raise MDSCs, induce antitumour responses with zoledronic acid, target monocytes, and kill macrophages
MCAR-MAIT Kill OVCAR3-FG tumour cells, have dual CAR/TCR targeting mechanisms, sustain antitumour capacity in presence of macrophages, and target TAMs
Prospects of macrophages in cancer

TAMs are an important immune cell type that shapes TME properties. Targeting TAMs effectively blocks the progression of various cancer types. Moreover, popularity of single-cell RNA-sequencing analysis enhances the mechanistic study and preclinical research of TAMs in TME (Tang et al., 2020; Tang et al., 2021a; Chung et al., 2023). Dissecting the heterogeneity and regulatory mechanism of macrophages in cancer at single-cell resolution leads to the discovery of novel macrophage-specific therapeutics targets from the TME, for example, MMT and MNT (Xue et al., 2021; Tang et al., 2022a; Tang et al., 2022b). They are emphasizing the adaptive plasticity of macrophages. MMTs, derived from M2 TAMs with protumour activities, lead to the formation of CAFs. These CAFs are key in driving cancer progression (Chen and Song, 2019; Li et al., 2020). The roles of MMT-derived CAFs in functions, including adaptive immunity suppression, drug resistance, metastasis, and promoting cancer cell stemness warrant investigation. Conversely, MNTs highlight the transformation of TAMs into neuron-like entities, influencing de novo neurogenesis in the TME (Tang et al., 2022b) and contributing to cancer-associated pain (Shepherd et al., 2018). This transition, while prevalent in NSCLC, is also seen in other tumours, emphasizing its importance in cancer pain and tumour innervation (Tang et al., 2022b). Given the impact of cancer pain on quality of life, especially in patients with advanced stages of the disease (Wang et al., 2021c), understanding MNT is vital for pain management strategies. Notably, these transitions were found to be mediated by a Smad3-centric gene network in TAMs, highlighting the potential of macrophage-targeted Smad3 interventions as a promising therapeutic approach in cancer immunotherapy (Tang et al., 2017; Feng et al., 2018; Tang et al., 2021b; Tang et al., 2022b). These new findings lead to the development of effective therapeutic approaches to enhance the efficiency of conventional anticancer treatments as well as the latest immunotherapies which are not primary or secondary resistant in patients with solid cancers (Kim et al., 2019b; Kim et al., 2020; Tang et al., 2020; Chung et al., 2021; Xue et al., 2021). Besides, macrophages are considered as a primary target of anti-inflammatory therapy for cancer prevention, their therapeutic potential is explored by new trials worldwide (Tang et al., 2019; Lee et al., 2021; Tang et al., 2022d). Despite the challenges, a better understanding of the immunodynamics of TAM shows a substantial potential for improving the therapeutic efficiency and clinical outcomes of cancer patients in the future.

 Author contributions

ZZJ: Writing–original draft, Writing–review and editing, Visualization. MK-KC: Writing–original draft, Writing–review and editing, Visualization. AS-WC: Data curation. K-TL: Writing–review and editing. XJ: Writing–review and editing. K-FT: Writing–review and editing. YW: Writing–review and editing. PM-KT: Writing–original draft, Writing–review & editing Conceptualization, Funding acquisition, Investigation, Resources, Supervision. Validation: All authors have read and agreed to the published version.

 Funding

The authors declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Research Grants Council of Hong Kong (14106518, 14111019, 14111720, and 24102723); RGC Postdoctoral Fellowship Scheme (PDFS2122-4S06); Hong Kong Government Health and Medical Research Fund (10210726); CU Medicine Passion for Perfection Scheme (PFP202210-004) and Faculty Innovation Award (4620528), CUHK Strategic Seed Funding for Collaborative Research Scheme (178896941), Direct Grant for Research (4054722), Postdoctoral Fellowship Scheme (NL/LT/PDFS 2022/0360/22lt and WW/PDFS 2023/0640/23en).

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Aburima A. Berger M. Spurgeon B. E. J. Webb B. A. Wraith K. S. Febbraio M. (2021). Thrombospondin-1 promotes hemostasis through modulation of cAMP signaling in blood platelets. Blood 137 (5), 678–689. 10.1182/blood.2020005382 Ahmed I. Ismail N. (2020). M1 and M2 macrophages polarization via mTORC1 influences innate immunity and outcome of ehrlichia infection. J. Cell. Immunol. 2 (3), 108–115. 10.33696/immunology.2.029 Ahmed S. Mohamed H. T. El-Husseiny N. El Mahdy M. M. Safwat G. Diab A. A. (2021). IL-8 secreted by tumor associated macrophages contribute to lapatinib resistance in HER2-positive locally advanced breast cancer via activation of Src/STAT3/ERK1/2-mediated EGFR signaling. Biochim. Biophys. Acta Mol. Cell. Res. 1868 (6), 118995. 10.1016/j.bbamcr.2021.118995 Akhtari M. Zargar S. J. Vojdanian M. Jamshidi A. Mahmoudi M. (2021). Monocyte-derived and M1 macrophages from ankylosing spondylitis patients released higher TNF-α and expressed more IL1B in response to BzATP than macrophages from healthy subjects. Sci. Rep. 11 (1), 17842. 10.1038/s41598-021-96262-2 Alhamdi J. R. Peng T. Al-Naggar I. M. Hawley K. L. Spiller K. L. Kuhn L. T. (2019). Controlled M1-to-M2 transition of aged macrophages by calcium phosphate coatings. Biomaterials 196, 90–99. 10.1016/j.biomaterials.2018.07.012 Argyle D. Kitamura T. (2018). Targeting macrophage-recruiting chemokines as a novel therapeutic strategy to prevent the progression of solid tumors. Front. Immunol. 9, 2629. 10.3389/fimmu.2018.02629 Astarita J. L. Dominguez C. X. Tan C. Guillen J. Pauli M. L. Labastida R. (2023). Treg specialization and functions beyond immune suppression. Clin. Exp. Immunol. 211 (2), 176–183. 10.1093/cei/uxac123 Badmann S. Heublein S. Mayr D. Reischer A. Liao Y. Kolben T. (2020). M2 macrophages infiltrating epithelial ovarian cancer express MDR1: a feature that may account for the poor prognosis. Cells 9 (5), 1224. 10.3390/cells9051224 Bai R. Li Y. Jian L. Yang Y. Zhao L. Wei M. (2022). The hypoxia-driven crosstalk between tumor and tumor-associated macrophages: mechanisms and clinical treatment strategies. Mol. Cancer 21 (1), 177. 10.1186/s12943-022-01645-2 Bain C. C. MacDonald A. S. (2022). The impact of the lung environment on macrophage development, activation and function: diversity in the face of adversity. Mucosal Immunol. 15 (2), 223–234. 10.1038/s41385-021-00480-w Balic J. J. Albargy H. Luu K. Kirby F. J. Jayasekara W. S. N. Mansell F. (2020). STAT3 serine phosphorylation is required for TLR4 metabolic reprogramming and IL-1β expression. Nat. Commun. 11 (1), 3816. 10.1038/s41467-020-17669-5 Becker W. Nagarkatti M. Nagarkatti P. S. (2018). miR-466a targeting of TGF-β2 contributes to FoxP3+ regulatory T cell differentiation in a murine model of allogeneic transplantation. Front. Immunol. 9, 688. 10.3389/fimmu.2018.00688 Beyranvand Nejad E. Labrie C. van Elsas M. J. Kleinovink J. W. Mittrücker H. W. Franken K. L. M. C. (2021). IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors. J. Immunother. Cancer 9 (4), e002460. 10.1136/jitc-2021-002460 Binnewies M. Pollack J. L. Rudolph J. Dash S. Abushawish M. Lee T. (2021). Targeting TREM2 on tumor-associated macrophages enhances immunotherapy. Cell. Rep. 37 (3), 109844. 10.1016/j.celrep.2021.109844 Bissinger S. Hage C. Wagner V. Maser I. P. Brand V. Schmittnaegel M. (2021). Macrophage depletion induces edema through release of matrix-degrading proteases and proteoglycan deposition. Sci. Transl. Med. 13 (598), eabd4550. 10.1126/scitranslmed.abd4550 Brempelis K. J. Cowan C. M. Kreuser S. A. Labadie K. P. Prieskorn B. M. Lieberman N. A. P. (2020). Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. J. Immunother. Cancer 8 (2), e001356. 10.1136/jitc-2020-001356 Cai J. Xia L. Li J. Ni S. Song H. Wu X. (2019). Tumor-associated macrophages derived TGF-β‒induced epithelial to mesenchymal transition in colorectal cancer cells through smad2,3-4/snail signaling pathway. Cancer Res. Treat. 51 (1), 252–266. 10.4143/crt.2017.613 Cao M. Isaac R. Yan W. Ruan X. Jiang L. Wan Y. (2022). Cancer-cell-secreted extracellular vesicles suppress insulin secretion through miR-122 to impair systemic glucose homeostasis and contribute to tumour growth. Nat. Cell. Biol. 24 (6), 954–967. 10.1038/s41556-022-00919-7 Cassetta L. Pollard J. W. (2018). Targeting macrophages: therapeutic approaches in cancer. Nat. Rev. Drug Discov. 17 (12), 887–904. 10.1038/nrd.2018.169 Cassetta L. Fragkogianni S. Sims A. H. Swierczak A. Forrester L. M. Zhang H. (2019). Human tumor-associated macrophage and monocyte transcriptional landscapes reveal cancer-specific reprogramming, biomarkers, and therapeutic targets. Cancer Cell. 35 (4), 588–602. 10.1016/j.ccell.2019.02.009 Celik M. O. Labuz D. Keye J. Glauben R. Machelska H. (2020). IL-4 induces M2 macrophages to produce sustained analgesia via opioids. JCI Insight 5 (4), e133093. 10.1172/jci.insight.133093 Chen X. Song E. (2019). Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18 (2), 99–115. 10.1038/s41573-018-0004-1 Chen H. M. van der Touw W. Wang Y. S. Kang K. Mai S. Zhang J. (2018). Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128 (12), 5647–5662. 10.1172/JCI97570 Chen J. Zhang K. Zhi Y. Wu Y. Chen B. Bai J. (2021). Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway. Clin. Transl. Med. 11 (9), e478. 10.1002/ctm2.478 Chen J. Zhao D. Zhang L. Zhang J. Xiao Y. Wu Q. (2022a). Tumor-associated macrophage (TAM)-derived CCL22 induces FAK addiction in esophageal squamous cell carcinoma (ESCC). Cell. Mol. Immunol. 19 (9), 1054–1066. 10.1038/s41423-022-00903-z Chen Z. Wu J. Wang L. Zhao H. He J. (2022b). Tumor-associated macrophages of the M1/M2 phenotype are involved in the regulation of malignant biological behavior of breast cancer cells through the EMT pathway. Med. Oncol. 39 (5), 83. 10.1007/s12032-022-01670-7 Cheng S. Li Z. Gao R. Xing B. Gao Y. Yang Y. (2021). A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 184 (3), 792–809 e23. 10.1016/j.cell.2021.01.010 Cho H. Kwon H. Y. Sharma A. Lee S. H. Liu X. Miyamoto N. (2022). Visualizing inflammation with an M1 macrophage selective probe via GLUT1 as the gating target. Nat. Commun. 13 (1), 5974. 10.1038/s41467-022-33526-z Choi W. Lee J. Lee J. Lee S. H. Kim S. (2019). Hepatocyte growth factor regulates macrophage transition to the M2 phenotype and promotes murine skeletal muscle regeneration. Front. Physiol. 10, 914. 10.3389/fphys.2019.00914 Christofides A. Strauss L. Yeo A. Cao C. Charest A. Boussiotis V. A. (2022). The complex role of tumor-infiltrating macrophages. Nat. Immunol. 23 (8), 1148–1156. 10.1038/s41590-022-01267-2 Chung S. Overstreet J. M. Li Y. Wang Y. Niu A. Wang S. (2018). TGF-beta promotes fibrosis after severe acute kidney injury by enhancing renal macrophage infiltration. JCI Insight 3 (21), e123563. 10.1172/jci.insight.123563 Chung J. Y. Chan M. K. K. Tang P. C. T. Chan A. S. W. Meng X. M. Chung J. S. Y. (2021). AANG: a natural compound formula for overcoming multidrug resistance via synergistic rebalancing the TGF-β/Smad signalling in hepatocellular carcinoma. J. Cell. Mol. Med. 25 (20), 9805–9813. 10.1111/jcmm.16928 Chung J. Y. Tang P. C. T. Chan M. K. K. Xue V. W. Huang X. R. Ng C. (2023). Smad3 is essential for polarization of tumor-associated neutrophils in non-small cell lung carcinoma. Nat. Commun. 14 (1), 1794. 10.1038/s41467-023-37515-8 Cioffi M. Trabulo S. Hidalgo M. Costello E. Greenhalf W. Erkan M. (2015). Inhibition of CD47 effectively targets pancreatic cancer stem cells via dual mechanisms. Clin. Cancer Res. 21 (10), 2325–2337. 10.1158/1078-0432.CCR-14-1399 Coussens L. M. Zitvogel L. Palucka A. K. (2013). Neutralizing tumour-promoting chronic inflammation: a magic bullet? Science 339 (6117), 286–291. 10.1126/science.1232227 Cowman S. J. Fuja D. G. Liu X. D. Tidwell R. S. S. Kandula N. Sirohi D. (2020). Macrophage HIF-1α is an independent prognostic indicator in kidney cancer. Clin. Cancer Res. 26 (18), 4970–4982. 10.1158/1078-0432.CCR-19-3890 Dang M. T. Gonzalez M. V. Gaonkar K. S. Rathi K. S. Young P. Arif S. (2021). Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality. Cell. Rep. 34 (13), 108917. 10.1016/j.celrep.2021.108917 De Vlaminck K. Van Hove H. Kancheva D. Scheyltjens I. Pombo Antunes A. R. Bastos J. (2022). Differential plasticity and fate of brain-resident and recruited macrophages during the onset and resolution of neuroinflammation. Immunity 55 (11), 2085–2102 e9. 10.1016/j.immuni.2022.09.005 DeRogatis J. M. Viramontes K. M. Neubert E. N. Henriquez M. L. Guerrero-Juarez C. F. Tinoco R. (2022). Targeting the PSGL-1 immune checkpoint promotes immunity to PD-1-resistant melanoma. Cancer Immunol. Res. 10 (5), 612–625. 10.1158/2326-6066.CIR-21-0690 Desterke C. Turhan A. G. Bennaceur-Griscelli A. Griscelli F. (2021). HLA-dependent heterogeneity and macrophage immunoproteasome activation during lung COVID-19 disease. J. Transl. Med. 19 (1), 290. 10.1186/s12967-021-02965-5 Diwanji N. Bergmann A. (2020). Basement membrane damage by ROS- and JNK-mediated Mmp2 activation drives macrophage recruitment to overgrown tissue. Nat. Commun. 11 (1), 3631. 10.1038/s41467-020-17399-8 Dong N. Shi X. Wang S. Gao Y. Kuang Z. Xie Q. (2019). M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br. J. Cancer 121 (1), 22–33. 10.1038/s41416-019-0482-x Dongre A. Weinberg R. A. (2019). New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat. Rev. Mol. Cell. Biol. 20 (2), 69–84. 10.1038/s41580-018-0080-4 Dooling L. J. Andrechak J. C. Hayes B. H. Kadu S. Zhang W. Pan R. (2023). Cooperative phagocytosis of solid tumours by macrophages triggers durable anti-tumour responses. Nat. Biomed. Eng. 7, 1081–1096. 10.1038/s41551-023-01031-3 Dorrington M. G. Fraser I. D. C. (2019). NF-κB signaling in macrophages: dynamics, crosstalk, and signal integration. Front. Immunol. 10, 705. 10.3389/fimmu.2019.00705 Elomaa H. Ahtiainen M. Väyrynen S. A. Ogino S. Nowak J. A. Lau M. C. (2023). Spatially resolved multimarker evaluation of CD274 (PD-L1)/PDCD1 (PD-1) immune checkpoint expression and macrophage polarisation in colorectal cancer. Br. J. Cancer 128 (11), 2104–2115. 10.1038/s41416-023-02238-6 Erlandsson A. Carlsson J. Lundholm M. Fält A. Andersson S. O. Andrén O. (2019). M2 macrophages and regulatory T cells in lethal prostate cancer. Prostate 79 (4), 363–369. 10.1002/pros.23742 Etzerodt A. Tsalkitzi K. Maniecki M. Damsky W. Delfini M. Baudoin E. (2019). Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell-mediated tumor regression. J. Exp. Med. 216 (10), 2394–2411. 10.1084/jem.20182124 Eyre R. Alférez D. G. Santiago-Gómez A. Spence K. McConnell J. C. Hart C. (2019). Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat. Commun. 10 (1), 5016. 10.1038/s41467-019-12807-0 Fang T. Huang Y. K. Wei J. Monterrosa Mena J. E. Lakey P. S. J. Kleinman M. T. (2022). Superoxide release by macrophages through NADPH oxidase activation dominating chemistry by isoprene secondary organic aerosols and quinones to cause oxidative damage on membranes. Environ. Sci. Technol. 56 (23), 17029–17038. 10.1021/acs.est.2c03987 Fekete T. Bencze D. Szabo A. Csoma E. Biro T. Bacsi A. (2018). Regulatory NLRs control the RLR-mediated type I interferon and inflammatory responses in human dendritic cells. Front. Immunol. 9, 2314. 10.3389/fimmu.2018.02314 Feng M. Tang P. M. K. Huang X. R. Sun S. F. You Y. K. Xiao J. (2018). TGF-Beta mediates renal fibrosis via the smad3-erbb4-IR long noncoding RNA Axis. Mol. Ther. 26 (1), 148–161. 10.1016/j.ymthe.2017.09.024 Flores-Toro J. A. Luo D. Gopinath A. Sarkisian M. R. Campbell J. J. Charo I. F. (2020). CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas. Proc. Natl. Acad. Sci. U. S. A. 117 (2), 1129–1138. 10.1073/pnas.1910856117 Frising U. C. Ribo S. Doglio M. G. Malissen B. van Loo G. Wullaert A. (2022). Nlrp3 inflammasome activation in macrophages suffices for inducing autoinflammation in mice. EMBO Rep. 23 (7), e54339. 10.15252/embr.202154339 Furuse M. Kuwabara H. Ikeda N. Hattori Y. Ichikawa T. Kagawa N. (2020). PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma. BMC Cancer 20 (1), 277. 10.1186/s12885-020-06755-y Garcia-Fojeda B. Minutti C. M. Montero-Fernández C. Stamme C. Casals C. (2022). Signaling pathways that mediate alveolar macrophage activation by surfactant protein A and IL-4. Front. Immunol. 13, 860262. 10.3389/fimmu.2022.860262 Greaney S. K. Algazi A. P. Tsai K. K. Takamura K. T. Chen L. Twitty C. G. (2020). Intratumoral plasmid IL12 electroporation therapy in patients with advanced melanoma induces systemic and intratumoral T-cell responses. Cancer Immunol. Res. 8 (2), 246–254. 10.1158/2326-6066.CIR-19-0359 Greene C. J. Nguyen J. A. Cheung S. M. Arnold C. R. Balce D. R. Wang Y. T. (2022). Macrophages disseminate pathogen associated molecular patterns through the direct extracellular release of the soluble content of their phagolysosomes. Nat. Commun. 13 (1), 3072. 10.1038/s41467-022-30654-4 Gu X. Shi Y. Dong M. Jiang L. Yang J. Liu Z. (2021). Exosomal transfer of tumor-associated macrophage-derived hsa_circ_0001610 reduces radiosensitivity in endometrial cancer. Cell. Death Dis. 12 (9), 818. 10.1038/s41419-021-04087-8 Guan X. Wang Y. Sun Y. Zhang C. Ma S. Zhang D. (2021). CTLA4-Mediated immunosuppression in glioblastoma is associated with the infiltration of macrophages in the tumor microenvironment. J. Inflamm. Res. 14, 7315–7329. 10.2147/JIR.S341981 Guerriero J. L. (2019). Macrophages: their untold story in T cell activation and function. Int. Rev. Cell. Mol. Biol. 342, 73–93. 10.1016/bs.ircmb.2018.07.001 Guilliams M. Svedberg F. R. (2021). Does tissue imprinting restrict macrophage plasticity? Nat. Immunol. 22 (2), 118–127. 10.1038/s41590-020-00849-2 Gunassekaran G. R. Poongkavithai Vadevoo S. M. Baek M. C. Lee B. (2021). M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials 278, 121137. 10.1016/j.biomaterials.2021.121137 Guo C. J. Atochina-Vasserman E. N. Abramova E. Smith L. C. Beers M. F. Gow A. J. (2019). Surfactant protein-D modulation of pulmonary macrophage phenotype is controlled by S-nitrosylation. Am. J. Physiol. Lung Cell. Mol. Physiol. 317 (5), L539–L549. 10.1152/ajplung.00506.2018 Haloul M. Oliveira E. R. A. Kader M. Wells J. Z. Tominello T. R. El Andaloussi A. (2019). mTORC1-mediated polarization of M1 macrophages and their accumulation in the liver correlate with immunopathology in fatal ehrlichiosis. Sci. Rep. 9 (1), 14050. 10.1038/s41598-019-50320-y Hannan C. J. Lewis D. O'Leary C. Waqar M. Brough D. Couper K. N. (2023). Increased circulating chemokines and macrophage recruitment in growing vestibular schwannomas. Neurosurgery 92 (3), 581–589. 10.1227/neu.0000000000002252 Haque A. Moriyama M. Kubota K. Ishiguro N. Sakamoto M. Chinju A. (2019). CD206+ tumor-associated macrophages promote proliferation and invasion in oral squamous cell carcinoma via EGF production. Sci. Rep. 9 (1), 14611. 10.1038/s41598-019-51149-1 He L. Jhong J. H. Chen Q. Huang K. Y. Strittmatter K. Kreuzer J. (2021). Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell. Rep. 37 (5), 109955. 10.1016/j.celrep.2021.109955 Hernandez G. E. Ma F. Martinez G. Firozabadi N. B. Salvador J. Juang L. J. (2022). Aortic intimal resident macrophages are essential for maintenance of the non-thrombogenic intravascular state. Nat. Cardiovasc Res. 1 (1), 67–84. 10.1038/s44161-021-00006-4 Hou Y. Zhu L. Tian H. Sun H. X. Wang R. Zhang L. (2018). IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis. Protein Cell. 9 (12), 1027–1038. 10.1007/s13238-018-0505-z Hsieh M. H. Chen P. C. Hsu H. Y. Liu J. C. Ho Y. S. Lin Y. J. (2023). Surfactant protein D inhibits lipid-laden foamy macrophages and lung inflammation in chronic obstructive pulmonary disease. Cell. Mol. Immunol. 20 (1), 38–50. 10.1038/s41423-022-00946-2 Hu M. Zhang R. Yang J. Zhao C. Liu W. Huang Y. (2023). The role of N-glycosylation modification in the pathogenesis of liver cancer. Cell. Death Dis. 14 (3), 222. 10.1038/s41419-023-05733-z Huang C. Hu F. Song D. Sun X. Liu A. Wu Q. (2022). EZH2-triggered methylation of SMAD3 promotes its activation and tumor metastasis. J. Clin. Invest. 132 (5), e152394. 10.1172/JCI152394 Hwang I. Kim J. W. Ylaya K. Chung E. J. Kitano H. Perry C. (2020). Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J. Transl. Med. 18 (1), 443. 10.1186/s12967-020-02618-z Im J. H. Buzzelli J. N. Jones K. Franchini F. Gordon-Weeks A. Markelc B. (2020). FGF2 alters macrophage polarization, tumour immunity and growth and can be targeted during radiotherapy. Nat. Commun. 11 (1), 4064. 10.1038/s41467-020-17914-x Irizarry-Caro R. A. McDaniel M. M. Overcast G. R. Jain V. G. Troutman T. D. Pasare C. (2020). TLR signaling adapter BCAP regulates inflammatory to reparatory macrophage transition by promoting histone lactylation. Proc. Natl. Acad. Sci. U. S. A. 117 (48), 30628–30638. 10.1073/pnas.2009778117 Ishii T. Mimura I. Nagaoka K. Naito A. Sugasawa T. Kuroda R. (2022). Effect of M2-like macrophages of the injured-kidney cortex on kidney cancer progression. Cell. Death Discov. 8 (1), 480. 10.1038/s41420-022-01255-3 Jaynes J. M. Sable R. Ronzetti M. Bautista W. Knotts Z. Abisoye-Ogunniyan A. (2020). Mannose receptor (CD206) activation in tumor-associated macrophages enhances adaptive and innate antitumor immune responses. Sci. Transl. Med. 12 (530), eaax6337. 10.1126/scitranslmed.aax6337 Jeong H. Kim S. Hong B. J. Lee C. J. Kim Y. E. Bok S. (2019). Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis. Cancer Res. 79 (4), 795–806. 10.1158/0008-5472.CAN-18-2545 Jia X. Yan B. Tian X. Liu Q. Jin J. Shi J. (2021). CD47/SIRPα pathway mediates cancer immune escape and immunotherapy. Int. J. Biol. Sci. 17 (13), 3281–3287. 10.7150/ijbs.60782 Jiang P. Gao W. Ma T. Wang R. Piao Y. Dong X. (2019). CD137 promotes bone metastasis of breast cancer by enhancing the migration and osteoclast differentiation of monocytes/macrophages. Theranostics 9 (10), 2950–2966. 10.7150/thno.29617 Jin M. Z. Jin W. L. (2020). The updated landscape of tumor microenvironment and drug repurposing. Signal Transduct. Target Ther. 5 (1), 166. 10.1038/s41392-020-00280-x Johnston R. J. Su L. J. Pinckney J. Critton D. Boyer E. Krishnakumar A. (2019). VISTA is an acidic pH-selective ligand for PSGL-1. Nature 574 (7779), 565–570. 10.1038/s41586-019-1674-5 Kaplanov I. Carmi Y. Kornetsky R. Shemesh A. Shurin G. V. Shurin M. R. (2019). Blocking IL-1β reverses the immunosuppression in mouse breast cancer and synergizes with anti-PD-1 for tumor abrogation. Proc. Natl. Acad. Sci. U. S. A. 116 (4), 1361–1369. 10.1073/pnas.1812266115 Katzenelenbogen Y. Sheban F. Yalin A. Yofe I. Svetlichnyy D. Jaitin D. A. (2020). Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell. 182 (4), 872–885. 10.1016/j.cell.2020.06.032 Kawasaki T. Ikegawa M. Yunoki K. Otani H. Ori D. Ishii K. J. (2022). Alveolar macrophages instruct CD8(+) T cell expansion by antigen cross-presentation in lung. Cell. Rep. 41 (11), 111828. 10.1016/j.celrep.2022.111828 Kennedy A. Waters E. Rowshanravan B. Hinze C. Williams C. Janman D. (2022). Differences in CD80 and CD86 transendocytosis reveal CD86 as a key target for CTLA-4 immune regulation. Nat. Immunol. 23 (9), 1365–1378. 10.1038/s41590-022-01289-w Kermanizadeh A. Brown D. M. Moritz W. Stone V. (2019). The importance of inter-individual Kupffer cell variability in the governance of hepatic toxicity in a 3D primary human liver microtissue model. Sci. Rep. 9 (1), 7295. 10.1038/s41598-019-43870-8 Kesh K. Gupta V. K. Durden B. Garrido V. Mateo-Victoriano B. Lavania S. P. (2020). Therapy resistance, cancer stem cells and ECM in cancer: the matrix reloaded. Cancers (Basel) 12 (10), 3067. 10.3390/cancers12103067 Kidwell C. U. Casalini J. R. Pradeep S. Scherer S. D. Greiner D. Bayik D. (2023). Transferred mitochondria accumulate reactive oxygen species, promoting proliferation. Elife 12, e85494. 10.7554/eLife.85494 Kim H. Wang S. Y. Kwak G. Yang Y. Kwon I. C. Kim S. H. (2019a). Exosome-guided phenotypic switch of M1 to M2 macrophages for cutaneous wound healing. Adv. Sci. (Weinh) 6 (20), 1900513. 10.1002/advs.201900513 Kim H. Chung H. Kim J. Choi D. H. Shin Y. Kang Y. G. (2019b). Macrophages-Triggered sequential remodeling of endothelium-interstitial matrix to form pre-metastatic niche in microfluidic tumor microenvironment. Adv. Sci. (Weinh) 6 (11), 1900195. 10.1002/advs.201900195 Kim S. H. Saeidi S. Zhong X. Gwak S. Y. Muna I. A. Park S. A. (2020). Breast cancer cell debris diminishes therapeutic efficacy through heme oxygenase-1-mediated inactivation of M1-like tumor-associated macrophages. Neoplasia 22 (11), 606–616. 10.1016/j.neo.2020.08.006 Kimura S. Nanbu U. Noguchi H. Harada Y. Kumamoto K. Sasaguri Y. (2019). Macrophage CCL22 expression in the tumor microenvironment and implications for survival in patients with squamous cell carcinoma of the tongue. J. Oral Pathol. Med. 48 (8), 677–685. 10.1111/jop.12885 Klichinsky M. Ruella M. Shestova O. Lu X. M. Best A. Zeeman M. (2020). Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38 (8), 947–953. 10.1038/s41587-020-0462-y Kohno K. Koya-Miyata S. Harashima A. Tsukuda T. Katakami M. Ariyasu T. (2021). Inflammatory M1-like macrophages polarized by NK-4 undergo enhanced phenotypic switching to an anti-inflammatory M2-like phenotype upon co-culture with apoptotic cells. J. Inflamm. (Lond) 18 (1), 2. 10.1186/s12950-020-00267-z Kraaij M. D. Savage N. D. L. van der Kooij S. W. Koekkoek K. Wang J. van den Berg J. M. (2010). Induction of regulatory T cells by macrophages is dependent on production of reactive oxygen species. Proc. Natl. Acad. Sci. U. S. A. 107 (41), 17686–17691. 10.1073/pnas.1012016107 Kumar R. Mickael C. Kassa B. Sanders L. Hernandez-Saavedra D. Koyanagi D. E. (2020). Interstitial macrophage-derived thrombospondin-1 contributes to hypoxia-induced pulmonary hypertension. Cardiovasc Res. 116 (12), 2021–2030. 10.1093/cvr/cvz304 La Fleur L. Botling J. He F. Pelicano C. Zhou C. He C. (2021). Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res. 81 (4), 956–967. 10.1158/0008-5472.CAN-20-1885 Lai Y. S. Wahyuningtyas R. Aui S. P. Chang K. T. (2019). Autocrine VEGF signalling on M2 macrophages regulates PD-L1 expression for immunomodulation of T cells. J. Cell. Mol. Med. 23 (2), 1257–1267. 10.1111/jcmm.14027 Lazarova M. Steinle A. (2019). Impairment of nkg2d-mediated tumor immunity by TGF-β. Front. Immunol. 10, 2689. 10.3389/fimmu.2019.02689 Lechner A. Henkel F. D. R. Hartung F. Bohnacker S. Alessandrini F. Gubernatorova E. O. (2022). Macrophages acquire a TNF-dependent inflammatory memory in allergic asthma. J. Allergy Clin. Immunol. 149 (6), 2078–2090. 10.1016/j.jaci.2021.11.026 Lee J. Son W. Hong J. Song Y. Yang C. S. Kim Y. H. (2021). Down-regulation of TNF-α via macrophage-targeted RNAi system for the treatment of acute inflammatory sepsis. J. Control Release 336, 344–353. 10.1016/j.jconrel.2021.06.022 Li D. Wu M. (2021). Pattern recognition receptors in health and diseases. Signal Transduct. Target Ther. 6 (1), 291. 10.1038/s41392-021-00687-0 Li F. Lv B. Liu Y. Hua T. Han J. Sun C. (2018). Blocking the CD47-SIRPα axis by delivery of anti-CD47 antibody induces antitumor effects in glioma and glioma stem cells. Oncoimmunology 7 (2), e1391973. 10.1080/2162402X.2017.1391973 Li W. Zhang X. Wu F. Zhou Y. Bao Z. Li H. (2019a). Gastric cancer-derived mesenchymal stromal cells trigger M2 macrophage polarization that promotes metastasis and EMT in gastric cancer. Cell. Death Dis. 10 (12), 918. 10.1038/s41419-019-2131-y Li K. Yang L. Li J. Guan C. Zhang S. Lao X. (2019b). TGFβ induces stemness through non-canonical AKT-FOXO3a axis in oral squamous cell carcinoma. EBioMedicine 48, 70–80. 10.1016/j.ebiom.2019.09.027 Li C. Xue V. W. Wang Q. M. Lian G. Y. Huang X. R. Lee T. L. (2020). The mincle/syk/NF-κB signaling circuit is essential for maintaining the protumoral activities of tumor-associated macrophages. Cancer Immunol. Res. 8 (8), 1004–1017. 10.1158/2326-6066.CIR-19-0782 Li X. Su X. Liu R. Pan Y. Fang J. Cao L. (2021a). HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene 40 (10), 1836–1850. 10.1038/s41388-020-01636-x Li Y. R. Zhou Y. Kim Y. J. Zhu Y. Ma F. Yu J. (2021b). Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy. Cell. Rep. Med. 2 (11), 100449. 10.1016/j.xcrm.2021.100449 Li H. Yang P. Wang J. Zhang J. Ma Q. Jiang Y. (2022a). HLF regulates ferroptosis, development and chemoresistance of triple-negative breast cancer by activating tumor cell-macrophage crosstalk. J. Hematol. Oncol. 15 (1), 2. 10.1186/s13045-021-01223-x Li M. He L. Zhu J. Zhang P. Liang S. (2022b). Targeting tumor-associated macrophages for cancer treatment. Cell. Biosci. 12 (1), 85. 10.1186/s13578-022-00823-5 Li Y. R. Brown J. Yu Y. Lee D. Zhou K. Dunn Z. S. (2022c). Targeting immunosuppressive tumor-associated macrophages using innate T cells for enhanced antitumor reactivity. Cancers (Basel) 14 (11), 2749. 10.3390/cancers14112749 Li Y. R. Dunn Z. S. Yu Y. Li M. Wang P. Yang L. (2023). Advancing cell-based cancer immunotherapy through stem cell engineering. Cell. Stem Cell. 30 (5), 592–610. 10.1016/j.stem.2023.02.009 Liang S. Ma H. Y. Zhong Z. Dhar D. Liu X. Xu J. (2019). NADPH oxidase 1 in liver macrophages promotes inflammation and tumor development in mice. Gastroenterology 156 (4), 1156–1172. 10.1053/j.gastro.2018.11.019 Liang N. Bing Z. Wang Y. Liu X. Guo C. Cao L. (2022). Clinical implications of EGFR-associated MAPK/ERK pathway in multiple primary lung cancer. Clin. Transl. Med. 12 (5), e847. 10.1002/ctm2.847 Lin Y. Xu J. Lan H. (2019). Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications. J. Hematol. Oncol. 12 (1), 76. 10.1186/s13045-019-0760-3 Lin S. C. Liao Y. C. Chen P. M. Yang Y. Y. Wang Y. H. Tung S. L. (2022). Periostin promotes ovarian cancer metastasis by enhancing M2 macrophages and cancer-associated fibroblasts via integrin-mediated NF-κB and TGF-β2 signaling. J. Biomed. Sci. 29 (1), 109. 10.1186/s12929-022-00888-x Lin Y. Huang S. Qi Y. Xie L. Jiang J. Li H. (2023). PSGL-1 is a novel tumor microenvironment prognostic biomarker with cervical high-grade squamous lesions and more. Front. Oncol. 13, 1052201. 10.3389/fonc.2023.1052201 Liu W. Sun Y. (2023). Epigenetics in glaucoma: a link between histone methylation and neurodegeneration. J. Clin. Invest. 133 (8), e173784. 10.1172/JCI173784 Liu L. Zhang L. Yang L. Li H. Li R. Yu J. (2017). Anti-CD47 antibody as a targeted therapeutic agent for human lung cancer and cancer stem cells. Front. Immunol. 8, 404. 10.3389/fimmu.2017.00404 Liu L. Ye Y. Zhu X. (2019). MMP-9 secreted by tumor associated macrophages promoted gastric cancer metastasis through a PI3K/AKT/Snail pathway. Biomed. Pharmacother. 117, 109096. 10.1016/j.biopha.2019.109096 Liu Y. Zugazagoitia J. Ahmed F. S. Henick B. S. Gettinger S. N. Herbst R. S. (2020). Immune cell PD-L1 colocalizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy. Clin. Cancer Res. 26 (4), 970–977. 10.1158/1078-0432.CCR-19-1040 Liu J. Geng X. Hou J. Wu G. (2021). New insights into M1/M2 macrophages: key modulators in cancer progression. Cancer Cell. Int. 21 (1), 389. 10.1186/s12935-021-02089-2 Liu J. Q. Zhang C. Zhang X. Yan J. Zeng C. Talebian F. (2022). Intratumoral delivery of IL-12 and IL-27 mRNA using lipid nanoparticles for cancer immunotherapy. J. Control Release 345, 306–313. 10.1016/j.jconrel.2022.03.021 Liu Z. L. Chen H. H. Zheng L. L. Sun L. P. Shi L. (2023a). Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct. Target Ther. 8 (1), 198. 10.1038/s41392-023-01460-1 Liu H. Zhao Q. Tan L. Wu X. Huang R. Zuo Y. (2023b). Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. Cancer Cell. 41 (4), 693–710 e8. 10.1016/j.ccell.2023.03.004 Liu Y. Wang Y. Yang Y. Weng L. Wu Q. Zhang J. (2023c). Emerging phagocytosis checkpoints in cancer immunotherapy. Signal Transduct. Target Ther. 8 (1), 104. 10.1038/s41392-023-01365-z Loeuillard E. Yang J. Buckarma E. Wang J. Liu Y. Conboy C. (2020). Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J. Clin. Invest. 130 (10), 5380–5396. 10.1172/JCI137110 Lopez de Andres J. Griñán-Lisón C. Jiménez G. Marchal J. A. (2020). Cancer stem cell secretome in the tumor microenvironment: a key point for an effective personalized cancer treatment. J. Hematol. Oncol. 13 (1), 136. 10.1186/s13045-020-00966-3 Lu C. Y. Santosa K. B. Jablonka-Shariff A. Vannucci B. Fuchs A. Turnbull I. (2020). Macrophage-derived vascular endothelial growth factor-A is integral to neuromuscular junction reinnervation after nerve injury. J. Neurosci. 40 (50), 9602–9616. 10.1523/JNEUROSCI.1736-20.2020 Lugano R. Ramachandran M. Dimberg A. (2020). Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 77 (9), 1745–1770. 10.1007/s00018-019-03351-7 Lundahl M. L. E. Mitermite M. Ryan D. G. Case S. Williams N. C. Yang M. (2022). Macrophage innate training induced by IL-4 and IL-13 activation enhances OXPHOS driven anti-mycobacterial responses. Elife 11, e74690. 10.7554/eLife.74690 Luo W. J. Yu S. L. Chang C. C. Chien M. H. Chang Y. L. Liao K. M. (2022). HLJ1 amplifies endotoxin-induced sepsis severity by promoting IL-12 heterodimerization in macrophages. Elife 11, e76094. 10.7554/eLife.76094 Lv W. Guo H. Wang J. Ma R. Niu L. Shang Y. (2023). PDLIM2 can inactivate the TGF-beta/Smad pathway to inhibit the malignant behavior of ovarian cancer cells. Cell. Biochem. Funct. 41, 542–552. 10.1002/cbf.3801 Maalej K. M. Merhi M. Inchakalody V. P. Mestiri S. Alam M. Maccalli C. (2023). CAR-cell therapy in the era of solid tumor treatment: current challenges and emerging therapeutic advances. Mol. Cancer 22 (1), 20. 10.1186/s12943-023-01723-z Maier B. Leader A. M. Chen S. T. Tung N. Chang C. LeBerichel J. (2020). A conserved dendritic-cell regulatory program limits antitumour immunity. Nature 580 (7802), 257–262. 10.1038/s41586-020-2134-y Maldonado L. A. G. Nascimento C. R. Rodrigues Fernandes N. A. Silva A. L. P. D'Silva N. J. Rossa C. Jr (2022). Influence of tumor cell-derived TGF-β on macrophage phenotype and macrophage-mediated tumor cell invasion. Int. J. Biochem. Cell. Biol. 153, 106330. 10.1016/j.biocel.2022.106330 Mantovani A. Allavena P. Marchesi F. Garlanda C. (2022). Macrophages as tools and targets in cancer therapy. Nat. Rev. Drug Discov. 21 (11), 799–820. 10.1038/s41573-022-00520-5 Marigo I. Trovato R. Hofer F. Ingangi V. Desantis G. Leone K. (2020). Disabled homolog 2 controls prometastatic activity of tumor-associated macrophages. Cancer Discov. 10 (11), 1758–1773. 10.1158/2159-8290.CD-20-0036 Mascarau R. Woottum M. Fromont L. Gence R. Cantaloube-Ferrieu V. Vahlas Z. (2023). Productive HIV-1 infection of tissue macrophages by fusion with infected CD4+ T cells. J. Cell. Biol. 222 (5), e202205103. 10.1083/jcb.202205103 Mattiola I. Pesant M. Tentorio P. F. Molgora M. Marcenaro E. Lugli E. (2015). Priming of human resting NK cells by autologous M1 macrophages via the engagement of IL-1β, IFN-β, and IL-15 pathways. J. Immunol. 195 (6), 2818–2828. 10.4049/jimmunol.1500325 McCaw T. R. Li M. Starenki D. Liu M. Cooper S. J. Arend R. C. (2019). Histone deacetylase inhibition promotes intratumoral CD8+ T-cell responses, sensitizing murine breast tumors to anti-PD1. Cancer Immunol. Immunother. 68 (12), 2081–2094. 10.1007/s00262-019-02430-9 Molgora M. Esaulova E. Vermi W. Hou J. Chen Y. Luo J. (2020). TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell. 182 (4), 886–900. 10.1016/j.cell.2020.07.013 Morhardt T. L. Hayashi A. Ochi T. Quirós M. Kitamoto S. Nagao-Kitamoto H. (2019). IL-10 produced by macrophages regulates epithelial integrity in the small intestine. Sci. Rep. 9 (1), 1223. 10.1038/s41598-018-38125-x Mosser D. M. Hamidzadeh K. Goncalves R. (2021). Macrophages and the maintenance of homeostasis. Cell. Mol. Immunol. 18 (3), 579–587. 10.1038/s41423-020-00541-3 Mouton A. J. Aitken N. M. Moak S. P. do Carmo J. M. da Silva A. A. Omoto A. C. M. (2023). Temporal changes in glucose metabolism reflect polarization in resident and monocyte-derived macrophages after myocardial infarction. Front. Cardiovasc Med. 10, 1136252. 10.3389/fcvm.2023.1136252 Muniz-Bongers L. R. McClain C. B. Saxena M. Bongers G. Merad M. Bhardwaj N. (2021). MMP2 and TLRs modulate immune responses in the tumor microenvironment. JCI Insight 6 (12), e144913. 10.1172/jci.insight.144913 Muraoka D. Seo N. Hayashi T. Tahara Y. Fujii K. Tawara I. (2019). Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance. J. Clin. Invest. 129 (3), 1278–1294. 10.1172/JCI97642 Nagata E. Masuda H. Nakayama T. Netsu S. Yuzawa H. Fujii N. (2019). Insufficient production of IL-10 from M2 macrophages impairs in vitro endothelial progenitor cell differentiation in patients with Moyamoya disease. Sci. Rep. 9 (1), 16752. 10.1038/s41598-019-53114-4 Nalio Ramos R. Missolo-Koussou Y. Gerber-Ferder Y. Bromley C. P. Bugatti M. Núñez N. G. (2022). Tissue-resident FOLR2(+) macrophages associate with CD8(+) T cell infiltration in human breast cancer. Cell. 185 (7), 1189–1207 e25. 10.1016/j.cell.2022.02.021 Natale G. Bocci G. (2023). Discovery and development of tumor angiogenesis assays. Methods Mol. Biol. 2572, 1–37. 10.1007/978-1-0716-2703-7_1 Nau G. J. Richmond J. F. L. Schlesinger A. Jennings E. G. Lander E. S. Young R. A. (2002). Human macrophage activation programs induced by bacterial pathogens. Proc. Natl. Acad. Sci. U. S. A. 99 (3), 1503–1508. 10.1073/pnas.022649799 Neu C. Thiele Y. Horr F. Beckers C. Frank N. Marx G. (2022). DAMPs released from proinflammatory macrophages induce inflammation in cardiomyocytes via activation of TLR4 and TNFR. Int. J. Mol. Sci. 23 (24), 15522. 10.3390/ijms232415522 Ning Y. Cui Y. Li X. Cao X. Chen A. Xu C. (2018). Co-culture of ovarian cancer stem-like cells with macrophages induced SKOV3 cells stemness via IL-8/STAT3 signaling. Biomed. Pharmacother. 103, 262–271. 10.1016/j.biopha.2018.04.022 Nost T. H. Alcala K. Urbarova I. Byrne K. S. Guida F. Sandanger T. M. (2021). Systemic inflammation markers and cancer incidence in the UK Biobank. Eur. J. Epidemiol. 36 (8), 841–848. 10.1007/s10654-021-00752-6 Ntokou A. Dave J. M. Kauffman A. C. Sauler M. Ryu C. Hwa J. (2021). Macrophage-derived PDGF-B induces muscularization in murine and human pulmonary hypertension. JCI Insight 6 (6), e139067. 10.1172/jci.insight.139067 Nunez S. Y. Ziblat A. Secchiari F. Torres N. I. Sierra J. M. Raffo Iraolagoitia X. L. (2018). Human M2 macrophages limit NK cell effector functions through secretion of TGF-beta and engagement of CD85j. J. Immunol. 200 (3), 1008–1015. 10.4049/jimmunol.1700737 O'Brien S. A. Orf J. Skrzypczynska K. M. Tan H. Kim J. DeVoss J. (2021). Activity of tumor-associated macrophage depletion by CSF1R blockade is highly dependent on the tumor model and timing of treatment. Cancer Immunol. Immunother. 70 (8), 2401–2410. 10.1007/s00262-021-02861-3 Onal S. Turker-Burhan M. Bati-Ayaz G. Yanik H. Pesen-Okvur D. (2021). Breast cancer cells and macrophages in a paracrine-juxtacrine loop. Biomaterials 267, 120412. 10.1016/j.biomaterials.2020.120412 Orange S. T. Leslie J. Ross M. Mann D. A. Wackerhage H. (2023). The exercise IL-6 enigma in cancer. Trends Endocrinol. Metab. 34, 749–763. 10.1016/j.tem.2023.08.001 Pereira J. A. Lanzar Z. Clark J. T. Hart A. P. Douglas B. B. Shallberg L. (2023). PD-1 and CTLA-4 exert additive control of effector regulatory T cells at homeostasis. Front. Immunol. 14, 997376. 10.3389/fimmu.2023.997376 Petty A. J. Owen D. H. Yang Y. Huang X. (2021). Targeting tumor-associated macrophages in cancer immunotherapy. Cancers (Basel) 13 (21), 5318. 10.3390/cancers13215318 Pfefferle M. Dubach I. L. Buzzi R. M. Dürst E. Schulthess-Lutz N. Baselgia L. (2023). Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity. J. Immunother. Cancer 11 (1), e005718. 10.1136/jitc-2022-005718 Pfirschke C. Zilionis R. Engblom C. Messemaker M. Zou A. E. Rickelt S. (2022). Macrophage-targeted therapy unlocks antitumoral cross-talk between ifnγ-secreting lymphocytes and IL12-producing dendritic cells. Cancer Immunol. Res. 10 (1), 40–55. 10.1158/2326-6066.CIR-21-0326 Piatakova A. Polakova I. Smahelova J. Johari S. D. Nunvar J. Smahel M. (2021). Distinct responsiveness of tumor-associated macrophages to immunotherapy of tumors with different mechanisms of major histocompatibility complex class I downregulation. Cancers (Basel) 13 (12), 3057. 10.3390/cancers13123057 Pu Y. Ji Q. (2022). Tumor-associated macrophages regulate PD-1/PD-L1 immunosuppression. Front. Immunol. 13, 874589. 10.3389/fimmu.2022.874589 Puig-Saus C. Sennino B. Peng S. Wang C. L. Pan Z. Yuen B. (2023). Neoantigen-targeted CD8(+) T cell responses with PD-1 blockade therapy. Nature 615 (7953), 697–704. 10.1038/s41586-023-05787-1 Qi Y. T. Jiang H. Wu W. T. Zhang F. L. Tian S. Y. Fan W. T. (2022). Homeostasis inside single activated phagolysosomes: quantitative and selective measurements of submillisecond dynamics of reactive oxygen and nitrogen species production with a nanoelectrochemical sensor. J. Am. Chem. Soc. 144 (22), 9723–9733. 10.1021/jacs.2c01857 Radharani N. N. V. Yadav A. S. Nimma R. Kumar T. V. S. Bulbule A. Chanukuppa V. (2022). Tumor-associated macrophage derived IL-6 enriches cancer stem cell population and promotes breast tumor progression via Stat-3 pathway. Cancer Cell. Int. 22 (1), 122. 10.1186/s12935-022-02527-9 Rahabi M. Jacquemin G. Prat M. Meunier E. AlaEddine M. Bertrand B. (2020). Divergent roles for macrophage C-type lectin receptors, dectin-1 and mannose receptors, in the intestinal inflammatory response. Cell. Rep. 30 (13), 4386–4398. 10.1016/j.celrep.2020.03.018 Rajamaki K. Taira A. Katainen R. Välimäki N. Kuosmanen A. Plaketti R. M. (2021). Genetic and epigenetic characteristics of inflammatory bowel disease-associated colorectal cancer. Gastroenterology 161 (2), 592–607. 10.1053/j.gastro.2021.04.042 Rapp M. Wintergerst M. W. M. Kunz W. G. Vetter V. K. Knott M. M. L. Lisowski D. (2019). CCL22 controls immunity by promoting regulatory T cell communication with dendritic cells in lymph nodes. J. Exp. Med. 216 (5), 1170–1181. 10.1084/jem.20170277 Ren L. Yi J. Yang Y. Li W. Zheng X. Liu J. (2022). Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis. Pharmacol. Res. 183, 106376. 10.1016/j.phrs.2022.106376 Revu S. Wu J. Henkel M. Rittenhouse N. Menk A. Delgoffe G. M. (2018). IL-23 and IL-1β drive human Th17 cell differentiation and metabolic reprogramming in absence of CD28 costimulation. Cell. Rep. 22 (10), 2642–2653. 10.1016/j.celrep.2018.02.044 Roda J. M. Wang Y. Sumner L. A. Phillips G. S. Marsh C. B. Eubank T. D. (2012). Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J. Immunol. 189 (6), 3168–3177. 10.4049/jimmunol.1103817 Rodriguez-Garcia A. Lynn R. C. Poussin M. Eiva M. A. Shaw L. C. O'Connor R. S. (2021). CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat. Commun. 12 (1), 877. 10.1038/s41467-021-20893-2 Romagnani P. Lasagni L. Annunziato F. Serio M. Romagnani S. (2004). CXC chemokines: the regulatory link between inflammation and angiogenesis. Trends Immunol. 25 (4), 201–209. 10.1016/j.it.2004.02.006 Ruiz-Blazquez P. Pistorio V. Fernández-Fernández M. Moles A. (2021). The multifaceted role of cathepsins in liver disease. J. Hepatol. 75 (5), 1192–1202. 10.1016/j.jhep.2021.06.031 Sa J. K. Chang N. Lee H. W. Cho H. J. Ceccarelli M. Cerulo L. (2020). Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 21 (1), 216. 10.1186/s13059-020-02140-x Sahraei M. Chaube B. Liu Y. Sun J. Kaplan A. Price N. L. (2019). Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response. J. Clin. Invest. 129 (12), 5518–5536. 10.1172/JCI127125 Sakama S. Kurusu K. Morita M. Oizumi T. Masugata S. Oka S. (2021). An enriched environment alters DNA repair and inflammatory responses after radiation exposure. Front. Immunol. 12, 760322. 10.3389/fimmu.2021.760322 Sanchez-Paulete A. R. Mateus-Tique J. Mollaoglu G. Nielsen S. R. Marks A. Lakshmi A. (2022). Targeting macrophages with CAR T cells delays solid tumor progression and enhances antitumor immunity. Cancer Immunol. Res. 10 (11), 1354–1369. 10.1158/2326-6066.CIR-21-1075 Saraiva M. Vieira P. O'Garra A. (2020). Biology and therapeutic potential of interleukin-10. J. Exp. Med. 217 (1), e20190418. 10.1084/jem.20190418 Scavuzzi B. M. van Drongelen V. Holoshitz J. (2022). HLA-G and the MHC cusp theory. Front. Immunol. 13, 814967. 10.3389/fimmu.2022.814967 Schaaf M. B. Garg A. D. Agostinis P. (2018). Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell. Death Dis. 9 (2), 115. 10.1038/s41419-017-0061-0 Schito L. Rey S. (2020). Hypoxia: turning vessels into vassals of cancer immunotolerance. Cancer Lett. 487, 74–84. 10.1016/j.canlet.2020.05.015 Serbulea V. Upchurch C. M. Ahern K. W. Bories G. Voigt P. DeWeese D. E. (2018). Macrophages sensing oxidized DAMPs reprogram their metabolism to support redox homeostasis and inflammation through a TLR2-Syk-ceramide dependent mechanism. Mol. Metab. 7, 23–34. 10.1016/j.molmet.2017.11.002 Sharma N. Atolagbe O. T. Ge Z. Allison J. P. (2021). LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J. Exp. Med. 218 (7), e20201811. 10.1084/jem.20201811 She L. Qin Y. Wang J. Liu C. Zhu G. Li G. (2018). Tumor-associated macrophages derived CCL18 promotes metastasis in squamous cell carcinoma of the head and neck. Cancer Cell. Int. 18, 120. 10.1186/s12935-018-0620-1 Shepherd A. J. Mickle A. D. Golden J. P. Mack M. R. Halabi C. M. de Kloet A. D. (2018). Macrophage angiotensin II type 2 receptor triggers neuropathic pain. Proc. Natl. Acad. Sci. U. S. A. 115 (34), E8057–E8066. 10.1073/pnas.1721815115 Shi Q. Shen Q. Liu Y. Shi Y. Huang W. Wang X. (2022). Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance. Cancer Cell. 40 (10), 1207–1222 e10. 10.1016/j.ccell.2022.08.012 Shinchi Y. Ishizuka S. Komohara Y. Matsubara E. Mito R. Pan C. (2022). The expression of PD-1 ligand 1 on macrophages and its clinical impacts and mechanisms in lung adenocarcinoma. Cancer Immunol. Immunother. 71 (11), 2645–2661. 10.1007/s00262-022-03187-4 Simonetta F. Lohmeyer J. K. Hirai T. Maas-Bauer K. Alvarez M. Wenokur A. S. (2021). Allogeneic CAR invariant natural killer T cells exert potent antitumor effects through host CD8 T-cell cross-priming. Clin. Cancer Res. 27 (21), 6054–6064. 10.1158/1078-0432.CCR-21-1329 Siu L. L. Wang D. Hilton J. Geva R. Rasco D. Perets R. (2022). Correction: first-in-Class anti-immunoglobulin-like transcript 4 myeloid-specific antibody MK-4830 abrogates a PD-1 resistance mechanism in patients with advanced solid tumors. Clin. Cancer Res. 28 (8), 1734. 10.1158/1078-0432.CCR-22-0564 Stanley E. R. Chitu V. (2014). CSF-1 receptor signaling in myeloid cells. Cold Spring Harb. Perspect. Biol. 6 (6), a021857. 10.1101/cshperspect.a021857 Su C. Zhang J. Yarden Y. Fu L. (2021). The key roles of cancer stem cell-derived extracellular vesicles. Signal Transduct. Target Ther. 6 (1), 109. 10.1038/s41392-021-00499-2 Sumitomo R. Hirai T. Fujita M. Murakami H. Otake Y. Huang C. L. (2019). PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer 136, 136–144. 10.1016/j.lungcan.2019.08.023 Sun L. Wang Q. Chen B. Zhao Y. Shen B. Wang H. (2018). Gastric cancer mesenchymal stem cells derived IL-8 induces PD-L1 expression in gastric cancer cells via STAT3/mTOR-c-Myc signal axis. Cell. Death Dis. 9 (9), 928. 10.1038/s41419-018-0988-9 Taban Q. Mumtaz P. T. Masoodi K. Z. Haq E. Ahmad S. M. (2022). Scavenger receptors in host defense: from functional aspects to mode of action. Cell. Commun. Signal 20 (1), 2. 10.1186/s12964-021-00812-0 Taki M. Abiko K. Baba T. Hamanishi J. Yamaguchi K. Murakami R. (2018). Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat. Commun. 9 (1), 1685. 10.1038/s41467-018-03966-7 Tan I. L. Arifa R. D. N. Rallapalli H. Kana V. Lao Z. Sanghrajka R. M. (2021). CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. Oncogene 40 (2), 396–407. 10.1038/s41388-020-01536-0 Tang P. M. Zhou S. Meng X. M. Wang Q. M. Li C. J. Lian G. Y. (2017). Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nat. Commun. 8, 14677. 10.1038/ncomms14677 Tang P. M. Nikolic-Paterson D. J. Lan H. Y. (2019). Macrophages: versatile players in renal inflammation and fibrosis. Nat. Rev. Nephrol. 15 (3), 144–158. 10.1038/s41581-019-0110-2 Tang P. M. Zhang Y. Y. Xiao J. Tang P. Chung J. Y. F. Li J. (2020). Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transition. Proc. Natl. Acad. Sci. U. S. A. 117 (34), 20741–20752. 10.1073/pnas.1917663117 Tang P. M. Zhang Y. Y. Hung J. S. C. Chung J. Y. F. Huang X. R. To K. F. (2021a). DPP4/CD32b/NF-κB circuit: a novel druggable target for inhibiting CRP-driven diabetic nephropathy. Mol. Ther. 29 (1), 365–375. 10.1016/j.ymthe.2020.08.017 Tang P. C. Chung J. Y. F. Xue V. W. W. Xiao J. Meng X. M. Huang X. R. (2021b). Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition. Adv. Sci. (Weinh) 9, e2101235. 10.1002/advs.202101235 Tang P. C. Chung J. Y. F. Xue V. W. W. Xiao J. Meng X. M. Huang X. R. (2022a). Smad3 promotes cancer-associated fibroblasts generation via macrophage-myofibroblast transition. Adv. Sci. (Weinh) 9 (1), e2101235. 10.1002/advs.202101235 Tang P. C. Chung J. Y. F. Liao J. Chan M. K. K. Chan A. S. W. Cheng G. (2022b). Single-cell RNA sequencing uncovers a neuron-like macrophage subset associated with cancer pain. Sci. Adv. 8 (40), eabn5535. 10.1126/sciadv.abn5535 Tang X. X. Shimada H. Ikegaki N. (2022c). Macrophage-mediated anti-tumor immunity against high-risk neuroblastoma. Genes Immun. 23 (3-4), 129–140. 10.1038/s41435-022-00172-w Tang P. C. Zhang Y. Y. Li J. S. F. Chan M. Chen J. Tang Y. (2022d). LncRNA-dependent mechanisms of transforming growth factor-β: from tissue fibrosis to cancer progression. Noncoding RNA 8 (3), 36. 10.3390/ncrna8030036 Taniguchi S. Elhance A. Van Duzer A. Kumar S. Leitenberger J. J. Oshimori N. (2020). Tumor-initiating cells establish an IL-33-TGF-β niche signaling loop to promote cancer progression. Science 369 (6501), eaay1813. 10.1126/science.aay1813 Tanito K. Nii T. Yokoyama Y. Oishi H. Shibata M. Hijii S. (2023). Engineered macrophages acting as a trigger to induce inflammation only in tumor tissues. J. Control Release 361, 885–895. 10.1016/j.jconrel.2023.04.010 Teng K. Y. Han J. Zhang X. Hsu S. H. He S. Wani N. A. (2017). Blocking the CCL2-CCR2 Axis using CCL2-neutralizing antibody is an effective therapy for hepatocellular cancer in a mouse model. Mol. Cancer Ther. 16 (2), 312–322. 10.1158/1535-7163.MCT-16-0124 Tian K. Du G. Wang X. Wu X. Li L. Liu W. (2022). MMP-9 secreted by M2-type macrophages promotes Wilms' tumour metastasis through the PI3K/AKT pathway. Mol. Biol. Rep. 49 (5), 3469–3480. 10.1007/s11033-022-07184-9 Tiwari J. K. Negi S. Kashyap M. Nizamuddin S. Singh A. Khattri A. (2021). Pan-cancer analysis shows enrichment of macrophages, overexpression of checkpoint molecules, inhibitory cytokines, and immune exhaustion signatures in EMT-high tumors. Front. Oncol. 11, 793881. 10.3389/fonc.2021.793881 Tlili A. Pintard C. Hurtado-Nedelec M. Liu D. Marzaioli V. Thieblemont N. (2023). ROCK2 interacts with p22phox to phosphorylate p47phox and to control NADPH oxidase activation in human monocytes. Proc. Natl. Acad. Sci. U. S. A. 120 (3), e2209184120. 10.1073/pnas.2209184120 Tomlins S. A. Khazanov N. A. Bulen B. J. Hovelson D. H. Shreve M. J. Lamb L. E. (2023). Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit. Commun. Med. (Lond) 3 (1), 14. 10.1038/s43856-023-00243-7 Trzupek D. Dunstan M. Cutler A. J. Lee M. Godfrey L. Jarvis L. (2020). Discovery of CD80 and CD86 as recent activation markers on regulatory T cells by protein-RNA single-cell analysis. Genome Med. 12 (1), 55. 10.1186/s13073-020-00756-z Tu M. M. Abdel-Hafiz H. A. Jones R. T. Jean A. Hoff K. J. Duex J. E. (2020). Inhibition of the CCL2 receptor, CCR2, enhances tumor response to immune checkpoint therapy. Commun. Biol. 3 (1), 720. 10.1038/s42003-020-01441-y Tu M. Klein L. Espinet E. Georgomanolis T. Wegwitz F. Li X. (2021a). TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat. Cancer 2 (11), 1185–1203. 10.1038/s43018-021-00258-w Tu D. Dou J. Wang M. Zhuang H. Zhang X. (2021b). M2 macrophages contribute to cell proliferation and migration of breast cancer. Cell. Biol. Int. 45 (4), 831–838. 10.1002/cbin.11528 Turrell F. K. Orha R. Guppy N. J. Gillespie A. Guelbert M. Starling C. (2023). Age-associated microenvironmental changes highlight the role of PDGF-C in ER(+) breast cancer metastatic relapse. Nat. Cancer 4 (4), 468–484. 10.1038/s43018-023-00525-y van der Sluis T. C. Beyrend G. van der Gracht E. T. I. Abdelaal T. Jochems S. P. Belderbos R. A. (2023). OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum. Cell. Rep. Med. 4 (3), 100939. 10.1016/j.xcrm.2023.100939 van Elsas M. J. Labrie C. Etzerodt A. Charoentong P. van Stigt Thans J. J. C. Van Hall T. (2023). Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. J. Immunother. Cancer 11 (3), e006433. 10.1136/jitc-2022-006433 Vayrynen J. P. Haruki K. Lau M. C. Väyrynen S. A. Zhong R. Dias Costa A. (2021). The prognostic role of macrophage polarization in the colorectal cancer microenvironment. Cancer Immunol. Res. 9 (1), 8–19. 10.1158/2326-6066.CIR-20-0527 Vidyarthi A. Khan N. Agnihotri T. Negi S. Das D. K. Aqdas M. (2018). TLR-3 stimulation skews M2 macrophages to M1 through IFN-αβ signaling and restricts tumor progression. Front. Immunol. 9, 1650. 10.3389/fimmu.2018.01650 Viitala M. Virtakoivu R. Tadayon S. Rannikko J. Jalkanen S. Hollmén M. (2019). Immunotherapeutic blockade of macrophage clever-1 reactivates the CD8+ T-cell response against immunosuppressive tumors. Clin. Cancer Res. 25 (11), 3289–3303. 10.1158/1078-0432.CCR-18-3016 Virtakoivu R. Rannikko J. H. Viitala M. Vaura F. Takeda A. Lönnberg T. (2021). Systemic blockade of clever-1 elicits lymphocyte activation alongside checkpoint molecule downregulation in patients with solid tumors: results from a phase I/II clinical trial. Clin. Cancer Res. 27 (15), 4205–4220. 10.1158/1078-0432.CCR-20-4862 Wang X. Khalil R. A. (2018). Matrix metalloproteinases, vascular remodeling, and vascular disease. Adv. Pharmacol. 81, 241–330. 10.1016/bs.apha.2017.08.002 Wang H. Sun Y. Zhou X. Chen C. Jiao L. Li W. (2020). CD47/SIRPα blocking peptide identification and synergistic effect with irradiation for cancer immunotherapy. J. Immunother. Cancer 8 (2), e000905. 10.1136/jitc-2020-000905 Wang Z. Guan D. Huo J. Biswas S. K. Huang Y. Yang Y. (2021a). IL-10 enhances human natural killer cell effector functions via metabolic reprogramming regulated by mTORC1 signaling. Front. Immunol. 12, 619195. 10.3389/fimmu.2021.619195 Wang G. Xu D. Zhang Z. Li X. Shi J. Sun J. (2021b). The pan-cancer landscape of crosstalk between epithelial-mesenchymal transition and immune evasion relevant to prognosis and immunotherapy response. NPJ Precis. Oncol. 5 (1), 56. 10.1038/s41698-021-00200-4 Wang K. Donnelly C. R. Jiang C. Liao Y. Luo X. Tao X. (2021c). STING suppresses bone cancer pain via immune and neuronal modulation. Nat. Commun. 12 (1), 4558. 10.1038/s41467-021-24867-2 Wang S. Yang Y. Ma P. Zha Y. Zhang J. Lei A. (2022). CAR-macrophage: an extensive immune enhancer to fight cancer. EBioMedicine 76, 103873. 10.1016/j.ebiom.2022.103873 Wang C. Barnoud C. Cenerenti M. Sun M. Caffa I. Kizil B. (2023). Dendritic cells direct circadian anti-tumour immune responses. Nature 614 (7946), 136–143. 10.1038/s41586-022-05605-0 Wei Z. Oh J. Flavell R. A. Crawford J. M. (2022). LACC1 bridges NOS2 and polyamine metabolism in inflammatory macrophages. Nature 609 (7926), 348–353. 10.1038/s41586-022-05111-3 Wen Y. Lambrecht J. Ju C. Tacke F. (2021). Hepatic macrophages in liver homeostasis and diseases-diversity, plasticity and therapeutic opportunities. Cell. Mol. Immunol. 18 (1), 45–56. 10.1038/s41423-020-00558-8 Willingham S. B. Volkmer J. P. Gentles A. J. Sahoo D. Dalerba P. Mitra S. S. (2012). The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc. Natl. Acad. Sci. U. S. A. 109 (17), 6662–6667. 10.1073/pnas.1121623109 Winkler J. Abisoye-Ogunniyan A. Metcalf K. J. Werb Z. (2020). Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11 (1), 5120. 10.1038/s41467-020-18794-x Wu H. Zhong Z. Wang A. Yuan C. Ning K. Hu H. (2020a). LncRNA FTX represses the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma via regulating the M1/M2 polarization of Kupffer cells. Cancer Cell. Int. 20, 266. 10.1186/s12935-020-01354-0 Wu J. Yang H. Cheng J. Zhang L. Ke Y. Zhu Y. (2020b). Knockdown of milk-fat globule EGF factor-8 suppresses glioma progression in GL261 glioma cells by repressing microglial M2 polarization. J. Cell. Physiol. 235 (11), 8679–8690. 10.1002/jcp.29712 Wu X. Wang Z. Shi J. Yu X. Li C. Liu J. (2022a). Macrophage polarization toward M1 phenotype through NF-κB signaling in patients with Behçet's disease. Arthritis Res. Ther. 24 (1), 249. 10.1186/s13075-022-02938-z Wu M. Zhang X. Zhang W. Chiou Y. S. Qian W. Liu X. (2022b). Cancer stem cell regulated phenotypic plasticity protects metastasized cancer cells from ferroptosis. Nat. Commun. 13 (1), 1371. 10.1038/s41467-022-29018-9 Wu B. Shi X. Jiang M. Liu H. (2023). Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment. Mol. Cancer 22 (1), 38. 10.1186/s12943-023-01748-4 Xia Q. Jia J. Hu C. Lu J. Li J. Xu H. (2022). Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma. Oncogene 41 (6), 865–877. 10.1038/s41388-021-02133-5 Xiao L. He Y. Peng F. Yang J. Yuan C. (2020). Endometrial cancer cells promote M2-like macrophage polarization by delivering exosomal miRNA-21 under hypoxia condition. J. Immunol. Res. 2020, 9731049. 10.1155/2020/9731049 Xie Y. Chen Z. Zhong Q. Zheng Z. Chen Y. Shangguan W. (2021). M2 macrophages secrete CXCL13 to promote renal cell carcinoma migration, invasion, and EMT. Cancer Cell. Int. 21 (1), 677. 10.1186/s12935-021-02381-1 Xie T. Fu D. J. Li Z. M. Lv D. J. Song X. L. Yu Y. Z. (2022). CircSMARCC1 facilitates tumor progression by disrupting the crosstalk between prostate cancer cells and tumor-associated macrophages via miR-1322/CCL20/CCR6 signaling. Mol. Cancer 21 (1), 173. 10.1186/s12943-022-01630-9 Xu M. Wang X. Li Y. Geng X. Jia X. Zhang L. (2021a). Arachidonic acid metabolism controls macrophage alternative activation through regulating oxidative phosphorylation in PPARγ dependent manner. Front. Immunol. 12, 618501. 10.3389/fimmu.2021.618501 Xu M. Wang Y. Xia R. Wei Y. Wei X. (2021b). Role of the CCL2-CCR2 signalling axis in cancer: mechanisms and therapeutic targeting. Cell. Prolif. 54 (10), e13115. 10.1111/cpr.13115 Xu Y. Zeng H. Jin K. Liu Z. Zhu Y. Xu L. (2022). Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer. J. Immunother. Cancer 10 (3), e003416. 10.1136/jitc-2021-003416 Xue V. W. Chung J. Y. F. Tang P. C. T. Chan A. S. W. To T. H. W. Chung J. S. Y. (2021). USMB-shMincle: a virus-free gene therapy for blocking M1/M2 polarization of tumor-associated macrophages. Mol. Ther. Oncolytics 23, 26–37. 10.1016/j.omto.2021.08.010 Yang H. D. Kim H. S. Kim S. Y. Na M. J. Yang G. Eun J. W. (2019). HDAC6 suppresses let-7i-5p to elicit TSP1/CD47-mediated anti-tumorigenesis and phagocytosis of hepatocellular carcinoma. Hepatology 70 (4), 1262–1279. 10.1002/hep.30657 Yang L. Shi P. Zhao G. Xu J. Peng W. Zhang J. (2020). Targeting cancer stem cell pathways for cancer therapy. Signal Transduct. Target Ther. 5 (1), 8. 10.1038/s41392-020-0110-5 Yang K. Xie Y. Xue L. Li F. Luo C. Liang W. (2023a). M2 tumor-associated macrophage mediates the maintenance of stemness to promote cisplatin resistance by secreting TGF-β1 in esophageal squamous cell carcinoma. J. Transl. Med. 21 (1), 26. 10.1186/s12967-022-03863-0 Yang Q. Dai H. Cheng Y. Wang B. Xu J. Zhang Y. (2023b). Oral feeding of nanoplastics affects brain function of mice by inducing macrophage IL-1 signal in the intestine. Cell. Rep. 42 (4), 112346. 10.1016/j.celrep.2023.112346 Yao R. R. Li J. H. Zhang R. Chen R. X. Wang Y. H. (2018). M2-polarized tumor-associated macrophages facilitated migration and epithelial-mesenchymal transition of HCC cells via the TLR4/STAT3 signaling pathway. World J. Surg. Oncol. 16 (1), 9. 10.1186/s12957-018-1312-y Yao Y. Zhang T. Ru X. Qian J. Tong Z. Li X. (2020). Constitutively expressed MHC class Ib molecules regulate macrophage M2b polarization and sepsis severity in irradiated mice. J. Leukoc. Biol. 107 (3), 445–453. 10.1002/JLB.1AB1219-125RR Yau E. Yang L. Chen Y. Umstead T. M. Atkins H. Katz Z. E. (2023). Surfactant protein A alters endosomal trafficking of influenza A virus in macrophages. Front. Immunol. 14, 919800. 10.3389/fimmu.2023.919800 Yen J. H. Huang W. C. Lin S. C. Huang Y. W. Chio W. T. Tsay G. J. (2022). Metabolic remodeling in tumor-associated macrophages contributing to antitumor activity of cryptotanshinone by regulating TRAF6-ASK1 axis. Mol. Ther. Oncolytics 26, 158–174. 10.1016/j.omto.2022.06.008 Yogev N. Bedke T. Kobayashi Y. Brockmann L. Lukas D. Regen T. (2022). CD4(+) T-cell-derived IL-10 promotes CNS inflammation in mice by sustaining effector T cell survival. Cell. Rep. 38 (13), 110565. 10.1016/j.celrep.2022.110565 Yu L. Yang F. Zhang F. Guo D. Li L. Wang X. (2018). CD69 enhances immunosuppressive function of regulatory T-cells and attenuates colitis by prompting IL-10 production. Cell. Death Dis. 9 (9), 905. 10.1038/s41419-018-0927-9 Yu Y. Ke L. Xia W. X. Xiang Y. Lv X. Bu J. (2019). Elevated levels of TNF-α and decreased levels of CD68-positive macrophages in primary tumor tissues are unfavorable for the survival of patients with nasopharyngeal carcinoma. Technol. Cancer Res. Treat. 18, 1533033819874807. 10.1177/1533033819874807 Yu Q. Wang Y. Dong L. He Y. Liu R. Yang Q. (2020). Regulations of glycolytic activities on macrophages functions in tumor and infectious inflammation. Front. Cell. Infect. Microbiol. 10, 287. 10.3389/fcimb.2020.00287 Yuan S. Stewart K. S. Yang Y. Abdusselamoglu M. D. Parigi S. M. Feinberg T. Y. (2022). Ras drives malignancy through stem cell crosstalk with the microenvironment. Nature 612 (7940), 555–563. 10.1038/s41586-022-05475-6 Zappasodi R. Serganova I. Cohen I. J. Maeda M. Shindo M. Senbabaoglu Y. (2021). CTLA-4 blockade drives loss of T(reg) stability in glycolysis-low tumours. Nature 591 (7851), 652–658. 10.1038/s41586-021-03326-4 Zeng X. Y. Xie H. Yuan J. Jiang X. Y. Yong J. H. Zeng D. (2019). M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression. Cancer Biol. Ther. 20 (7), 956–966. 10.1080/15384047.2018.1564567 Zhang F. Parayath N. N. Ene C. I. Stephan S. B. Koehne A. L. Coon M. E. (2019). Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 10 (1), 3974. 10.1038/s41467-019-11911-5 Zhang F. Mears J. R. Shakib L. Beynor J. I. Shanaj S. Korsunsky I. (2021a). IFN-γ and TNF-α drive a CXCL10+ CCL2+ macrophage phenotype expanded in severe COVID-19 lungs and inflammatory diseases with tissue inflammation. Genome Med. 13 (1), 64. 10.1186/s13073-021-00881-3 Zhang B. Zhang Y. Jiang X. Su H. Wang Q. Wudu M. (2021b). JMJD8 promotes malignant progression of lung cancer by maintaining EGFR stability and EGFR/PI3K/AKT pathway activation. J. Cancer 12 (4), 976–987. 10.7150/jca.50234 Zhang S. Rautela J. Bediaga N. G. Kolesnik T. B. You Y. Nie J. (2023). CIS controls the functional polarization of GM-CSF-derived macrophages. Cell. Mol. Immunol. 20 (1), 65–79. 10.1038/s41423-022-00957-z Zhao S. Mi Y. Guan B. Zheng B. Wei P. Gu Y. (2020). Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer. J. Hematol. Oncol. 13 (1), 156. 10.1186/s13045-020-00991-2 Zhao D. Yang F. Wang Y. Li S. Li Y. Hou F. (2022a). ALK1 signaling is required for the homeostasis of Kupffer cells and prevention of bacterial infection. J. Clin. Invest. 132 (3), e150489. 10.1172/JCI150489 Zhao X. Di Q. Liu H. Quan J. Ling J. Zhao Z. (2022b). MEF2C promotes M1 macrophage polarization and Th1 responses. Cell. Mol. Immunol. 19 (4), 540–553. 10.1038/s41423-022-00841-w Zhou Z. Peng Y. Wu X. Meng S. Yu W. Zhao J. (2019). CCL18 secreted from M2 macrophages promotes migration and invasion via the PI3K/Akt pathway in gallbladder cancer. Cell. Oncol. (Dordr) 42 (1), 81–92. 10.1007/s13402-018-0410-8 Zhou H. M. Zhang J. G. Zhang X. Li Q. (2021). Targeting cancer stem cells for reversing therapy resistance: mechanism, signaling, and prospective agents. Signal Transduct. Target Ther. 6 (1), 62. 10.1038/s41392-020-00430-1 Zhou Y. Takano T. Li X. Wang Y. Wang R. Zhu Z. (2022). β-elemene regulates M1-M2 macrophage balance through the ERK/JNK/P38 MAPK signaling pathway. Commun. Biol. 5 (1), 519. 10.1038/s42003-022-03369-x Zhou Y. Cheng L. Liu L. Li X. (2023a). NK cells are never alone: crosstalk and communication in tumour microenvironments. Mol. Cancer 22 (1), 34. 10.1186/s12943-023-01737-7 Zhou H. Gan M. Jin X. Dai M. Wang Y. Lei Y. (2023b). [Corrigendum] miR‑382 inhibits breast cancer progression and metastasis by affecting the M2 polarization of tumor‑associated macrophages by targeting PGC‑1α. Int. J. Oncol. 62 (1), 1. 10.3892/ijo.2022.5449 Zhu R. Gires O. Zhu L. Liu J. Li J. Yang H. (2019). TSPAN8 promotes cancer cell stemness via activation of sonic Hedgehog signaling. Nat. Commun. 10 (1), 2863. 10.1038/s41467-019-10739-3